US20020164729A1 - Production of polyhydroxyalkanoates from polyols - Google Patents
Production of polyhydroxyalkanoates from polyols Download PDFInfo
- Publication number
- US20020164729A1 US20020164729A1 US09/909,574 US90957401A US2002164729A1 US 20020164729 A1 US20020164729 A1 US 20020164729A1 US 90957401 A US90957401 A US 90957401A US 2002164729 A1 US2002164729 A1 US 2002164729A1
- Authority
- US
- United States
- Prior art keywords
- diol
- hydroxybutyrate
- pha
- hydroxyalkanoate
- organism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229920000903 polyhydroxyalkanoate Polymers 0.000 title claims abstract description 80
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 24
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 title claims description 69
- 229920005862 polyol Polymers 0.000 title 1
- 150000003077 polyols Chemical class 0.000 title 1
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 claims abstract description 56
- 150000002009 diols Chemical class 0.000 claims abstract description 50
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 claims abstract description 40
- 241000588724 Escherichia coli Species 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 26
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims abstract description 22
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims abstract description 22
- 102000004190 Enzymes Human genes 0.000 claims abstract description 20
- 108090000790 Enzymes Proteins 0.000 claims abstract description 20
- 239000000178 monomer Substances 0.000 claims abstract description 20
- ALRHLSYJTWAHJZ-UHFFFAOYSA-M 3-hydroxypropionate Chemical compound OCCC([O-])=O ALRHLSYJTWAHJZ-UHFFFAOYSA-M 0.000 claims abstract description 14
- 230000000694 effects Effects 0.000 claims abstract description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 10
- IWHLYPDWHHPVAA-UHFFFAOYSA-N 6-hydroxyhexanoic acid Chemical compound OCCCCCC(O)=O IWHLYPDWHHPVAA-UHFFFAOYSA-N 0.000 claims abstract description 9
- PHOJOSOUIAQEDH-UHFFFAOYSA-N 5-hydroxypentanoic acid Chemical compound OCCCCC(O)=O PHOJOSOUIAQEDH-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000013772 propylene glycol Nutrition 0.000 claims abstract description 7
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 claims abstract description 6
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims abstract description 4
- ALQSHHUCVQOPAS-UHFFFAOYSA-N Pentane-1,5-diol Chemical compound OCCCCCO ALQSHHUCVQOPAS-UHFFFAOYSA-N 0.000 claims abstract description 4
- 101100246459 Escherichia coli (strain K12) puuC gene Proteins 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 20
- 101150061843 dhaT gene Proteins 0.000 claims description 16
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 claims description 12
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 10
- 102000005870 Coenzyme A Ligases Human genes 0.000 claims description 9
- 108010011449 Long-chain-fatty-acid-CoA ligase Proteins 0.000 claims description 9
- 108010010718 poly(3-hydroxyalkanoic acid) synthase Proteins 0.000 claims description 9
- 102000004316 Oxidoreductases Human genes 0.000 claims description 7
- 108090000854 Oxidoreductases Proteins 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 6
- 102100026105 3-ketoacyl-CoA thiolase, mitochondrial Human genes 0.000 claims description 5
- 108010003902 Acetyl-CoA C-acyltransferase Proteins 0.000 claims description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical group CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 5
- 102000004357 Transferases Human genes 0.000 claims description 5
- 108090000992 Transferases Proteins 0.000 claims description 5
- 108091000039 acetoacetyl-CoA reductase Proteins 0.000 claims description 5
- FMHKPLXYWVCLME-UHFFFAOYSA-N 4-hydroxy-valeric acid Chemical compound CC(O)CCC(O)=O FMHKPLXYWVCLME-UHFFFAOYSA-N 0.000 claims description 4
- 108010001058 Acyl-CoA Dehydrogenase Proteins 0.000 claims description 4
- 102000002735 Acyl-CoA Dehydrogenase Human genes 0.000 claims description 4
- 102000008170 Aldehyde Oxidoreductases Human genes 0.000 claims description 4
- 108010060441 Aldehyde Oxidoreductases Proteins 0.000 claims description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical group OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 4
- 241000193033 Azohydromonas lata Species 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- AFENDNXGAFYKQO-VKHMYHEASA-N (S)-2-hydroxybutyric acid Chemical compound CC[C@H](O)C(O)=O AFENDNXGAFYKQO-VKHMYHEASA-N 0.000 claims 3
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 claims 3
- HPMGFDVTYHWBAG-UHFFFAOYSA-N 3-hydroxyhexanoic acid Chemical compound CCCC(O)CC(O)=O HPMGFDVTYHWBAG-UHFFFAOYSA-N 0.000 claims 3
- WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims 3
- 241000589151 Azotobacter Species 0.000 claims 1
- 241000589519 Comamonas Species 0.000 claims 1
- 241000252867 Cupriavidus metallidurans Species 0.000 claims 1
- 241000588748 Klebsiella Species 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 28
- 229920000642 polymer Polymers 0.000 abstract description 22
- 229920001577 copolymer Polymers 0.000 abstract description 10
- 230000014509 gene expression Effects 0.000 abstract description 8
- 229920001519 homopolymer Polymers 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 3
- 239000000543 intermediate Substances 0.000 abstract description 3
- 239000007858 starting material Substances 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 abstract 11
- 238000012017 passive hemagglutination assay Methods 0.000 abstract 11
- OORRCVPWRPVJEK-UHFFFAOYSA-N 2-oxidanylethanoic acid Chemical compound OCC(O)=O.OCC(O)=O OORRCVPWRPVJEK-UHFFFAOYSA-N 0.000 abstract 1
- KVZLHPXEUGJPAH-UHFFFAOYSA-N 2-oxidanylpropanoic acid Chemical compound CC(O)C(O)=O.CC(O)C(O)=O KVZLHPXEUGJPAH-UHFFFAOYSA-N 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 39
- 239000013612 plasmid Substances 0.000 description 28
- 239000002609 medium Substances 0.000 description 17
- 239000000758 substrate Substances 0.000 description 15
- 230000037361 pathway Effects 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 229960000723 ampicillin Drugs 0.000 description 10
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- 241001528539 Cupriavidus necator Species 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 101000746457 Neisseria gonorrhoeae UPF0213 protein in glnA 3'region Proteins 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 8
- AKXKFZDCRYJKTF-UHFFFAOYSA-N 3-Hydroxypropionaldehyde Chemical compound OCCC=O AKXKFZDCRYJKTF-UHFFFAOYSA-N 0.000 description 7
- 101100489695 Cupriavidus necator gbd gene Proteins 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000010348 incorporation Methods 0.000 description 7
- 239000013615 primer Substances 0.000 description 7
- 241000186570 Clostridium kluyveri Species 0.000 description 6
- -1 Poly(4HB) Polymers 0.000 description 6
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 101150048611 phaC gene Proteins 0.000 description 5
- 229920001013 poly(3-hydroxybutyrate-co-4-hydroxybutyrate) Polymers 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 4
- 102000004594 DNA Polymerase I Human genes 0.000 description 4
- 108010017826 DNA Polymerase I Proteins 0.000 description 4
- 239000003155 DNA primer Substances 0.000 description 4
- 239000007836 KH2PO4 Substances 0.000 description 4
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 4
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 4
- 101100297400 Rhizobium meliloti (strain 1021) phaAB gene Proteins 0.000 description 4
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- MPTQRFCYZCXJFQ-UHFFFAOYSA-L copper(II) chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Cu+2] MPTQRFCYZCXJFQ-UHFFFAOYSA-L 0.000 description 4
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 4
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
- 229910000397 disodium phosphate Inorganic materials 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 4
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 4
- 229960003495 thiamine Drugs 0.000 description 4
- 235000019157 thiamine Nutrition 0.000 description 4
- 239000011721 thiamine Substances 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- RZLVQBNCHSJZPX-UHFFFAOYSA-L zinc sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Zn+2].[O-]S([O-])(=O)=O RZLVQBNCHSJZPX-UHFFFAOYSA-L 0.000 description 4
- 108010011958 1,3-propanediol dehydrogenase Proteins 0.000 description 3
- ALRHLSYJTWAHJZ-UHFFFAOYSA-N 3-hydroxypropionic acid Chemical compound OCCC(O)=O ALRHLSYJTWAHJZ-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 101150055425 aldh gene Proteins 0.000 description 3
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 3
- 239000005516 coenzyme A Substances 0.000 description 3
- 229940093530 coenzyme a Drugs 0.000 description 3
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108010077385 Coenzyme A-Transferases Proteins 0.000 description 2
- 102000010079 Coenzyme A-Transferases Human genes 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 241001600125 Delftia acidovorans Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- 101100463818 Pseudomonas oleovorans phaC1 gene Proteins 0.000 description 2
- 101100490769 Rattus norvegicus Aldh1a1 gene Proteins 0.000 description 2
- 101100280476 Streptococcus pneumoniae (strain ATCC BAA-255 / R6) fabM gene Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108010069175 acyl-CoA transferase Proteins 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 101150054334 alkK gene Proteins 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- GHLKSLMMWAKNBM-UHFFFAOYSA-N dodecane-1,12-diol Chemical compound OCCCCCCCCCCCCO GHLKSLMMWAKNBM-UHFFFAOYSA-N 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 101150081090 gbd gene Proteins 0.000 description 2
- 150000001261 hydroxy acids Chemical class 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 101150046540 phaA gene Proteins 0.000 description 2
- 101150110984 phaB gene Proteins 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical group OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- BAMBWCGEVIAQBF-CITAKDKDSA-N 4-hydroxybutyryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 BAMBWCGEVIAQBF-CITAKDKDSA-N 0.000 description 1
- 101150056162 4hbD gene Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000588919 Citrobacter freundii Species 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 241000702191 Escherichia virus P1 Species 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 241000588749 Klebsiella oxytoca Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 101000907829 Klebsiella pneumoniae 1,3-propanediol dehydrogenase Proteins 0.000 description 1
- 101100331459 Klebsiella pneumoniae dhaT gene Proteins 0.000 description 1
- 229920001736 Metabolix Polymers 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000589781 Pseudomonas oleovorans Species 0.000 description 1
- 241000481518 Ralstonia eutropha H16 Species 0.000 description 1
- 241000588746 Raoultella planticola Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000003965 capillary gas chromatography Methods 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000002962 chemical mutagen Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- FOTKYAAJKYLFFN-UHFFFAOYSA-N decane-1,10-diol Chemical compound OCCCCCCCCCCO FOTKYAAJKYLFFN-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- JBFHTYHTHYHCDJ-UHFFFAOYSA-N gamma-caprolactone Chemical compound CCC1CCC(=O)O1 JBFHTYHTHYHCDJ-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012269 metabolic engineering Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- OEIJHBUUFURJLI-UHFFFAOYSA-N octane-1,8-diol Chemical compound OCCCCCCCCO OEIJHBUUFURJLI-UHFFFAOYSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- WUWHFEHKUQVYLF-UHFFFAOYSA-M sodium;2-aminoacetate Chemical compound [Na+].NCC([O-])=O WUWHFEHKUQVYLF-UHFFFAOYSA-M 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- PIAOXUVIBAKVSP-UHFFFAOYSA-N γ-hydroxybutyraldehyde Chemical compound OCCCC=O PIAOXUVIBAKVSP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/62—Carboxylic acid esters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/62—Carboxylic acid esters
- C12P7/625—Polyesters of hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
Definitions
- This invention is generally in the field of production of polyhydroxyalkanoates (PHAs) by genetic engineering of bacteria.
- PHA polymers containing the monomer 4-hydroxybutyrate (4HB), such as poly(3-hydroxybutyrate-co-4-hydroxybutyrate) (PHB4HB) (Doi, 1995, Macromol Symp. 98:585-99) or 4-hydroxyvalerate and 4-hydroxyhexanoate containing PHA polyesters have been described, for example, in Valentin et al., 1992, Appl. Microbiol. Biotechnol. 36:507-14 and Valentin et al., 1994, Appl. Microbiol. Biotechnol. 40:710-16.
- Production of PHB4HB has been accomplished by feeding glucose and 4HB or a substrate that is converted to 4-hydroxybutyrate to Ralstonia eutropha (Kunioka, et al., 1988, Polym. Commun. 29:174; Doi, et al., 1990, Int. J. Biol. Macromol. 12:106; Nakamura, et al., 1992, Macromolecules 25:423), to Alcaligenes latus (Hiramitsu, et al., 1993, Biotechnol. Lett. 15:461), to Pseudomonas acidovorans (Kimura, et al., 1992, Biotechnol. Lett.
- Substrates that are converted to 4HB include 1,4-butanediol, 1,6-hexanediol, 1,8-octanediol, 1,10-decanediol, 1,12-dodecanediol and gamma-butyrolactone.
- the PHB4HB copolymers can be produced with a range of monomer compositions which provide a range of polymer properties. In particular, as the amount of 4HB increases above 15 wt. %, the melting temperature (T m ) decreases below 130° C. and the elongation to break increases above 400% (Saito, et al., 1996, Polym. Int. 39:169).
- PHAs containing 4-hydroxybutyrate (4HB) monomers are produced directly from 1,4-butanediol; PHAs containing 5-hydroxyvalerate (5HV) are produced from 1,5-pentanediol; PHAs containing 6-hydroxyhexanoate (6HH) are produced from 1,6-hexanediol; PHAs containing 3-hydroxypropionate (3HP) are produced from 1,3-propanediol (also called propylene glycol); PHAs containing 2-hydroxypropionate (2HP, lactate) are produced from 1,2-propanediol (propylene glycol); PHAs containing 2-hydroxyethanoate (2HE, glycolate) are produced from 1,2-ethanediol (ethylene glycol).
- PHA polymers are readily recovered and industrially useful as polymers or as starting materials for a range of chemical intermediates.
- FIG. 1 illustrates the pathway from 1,4-butanediol to 4-hydroxybutyryl-CoA that is employed in one embodiment.
- Processes are provided whereby additional genes are introduced into microorganisms which have been genetically engineered to produce PHA so that the improved strains produce PHA homopolymers and copolymers directly from simple alcohol and sugar substrates.
- These processes are based on recombinant bacteria e.g., Escherichia coli as a production organism and PHA biosynthetic genes from PHA-producing microbes such as Ralstonia eutropha or Alcaligenes latus although many other sources of PHA genes are now known (Madison & Huisman, 1999, Microbiol . & Molecular Biology Reviews, 63:21-53).
- Recombinant E. coli has many advantages over the wild type PHA producing organisms including ease of genetic manipulation, complete availability of the genome sequence, fast growth rate, flexibility of growth substrates and ready lysis.
- genes for the entire pathway illustrated in FIG. 1 are introduced into the production organism.
- An organism that does not naturally produce PHAs such as Escherichia coli, may be used.
- a number of recombinant E. coli PHB production systems have been described (Madison & Huisman, 1999, Microbiology & Molecular Biology Reviews, 63:21-53).
- the genes encoding a diol oxidoreductase and aldehyde dehydrogenase are introduced into this host.
- the diol oxidoreductase converts the substrate to 4-hydroxybutyraldehyde, which is then converted to 4-hydroxybutyrate by the aldehyde dehydrogenase.
- the diol oxidoreductase converts the substrate to 3-hydroxypropionaldehyde, which is then converted to 3-hydroxypropionate by the aldehyde dehydrogenase.
- Other diols may be treated in an analogous way. In some instances incorporation into PHA of a hydroxyacid that is two carbons shorter than the diol feedstock may occur.
- 4HB units may be produced in the polymer as a result of feeding 1,6-hexanediol.
- an exogenous acyl-CoA transferase or acyl-CoA synthetase may be included to facilitate activation of the hydroxyacid with coenzyme A.
- the activated monomer may then be incorporated into PHA by the action of an appropriate PHA synthase present in the production host.
- the enzyme activities provide a system for the synthesis in the production host of a polymer containing one or more monomer types, depending upon the diol feedstocks.
- the production host will also contain the ⁇ -ketothiolase and acetoacetyl-CoA reductase genes, the products of which convert acetyl-CoA to 3HB-CoA.
- Acetyl-CoA may be derived from the diol or from another carbon source such as a sugar.
- Both 3HB-CoA and hydroxyacyl-CoAs such as those mentioned above can be accepted by various PHA synthases such as the one expressed in the recombinant host, and therefore copolymers of PHB are synthesized by the recombinant host.
- the diol can be fed to the cells either during growth or after a separate growth phase, either alone or in combination with at least one other feedstock, such as a sugar, and PHA is accumulated within the cells.
- a recombinant organism that naturally contains at least part of the pathway shown in FIG. 1 can be used.
- one or more of the activities discussed above can be derived from the endogenous machinery of the host. For example, only diol oxidoreductase and aldehyde dehydrogenase might be expressed in R.
- eutropha a natural PHA-producing organism, to augment its ability to convert 1,4-butanediol to 4HB, and the natural ability of the host may be relied upon to accomplish the rest of the necessary metabolic steps.
- Many natural PHA-producing organisms are well-known to those skilled in the art (Braunegg et al. 1998, J. Biotechnology 65:127-61). If the host is not capable of PHA production, a PHA synthase or an entire PHB biosynthetic pathway and optionally an exogenous acyl-CoA transferase or acyl-CoA synthetase may be introduced into this organism to enable PHA production.
- the diol can be fed to the cells either during growth or after a separate growth phase, either alone or in combination with at least one other feedstock, such as a sugar, and PHA is accumulated within the cells.
- the implementation of the production of PHAs with diol feedstocks is not limited to bacteria as described in the examples.
- the same genes may be introduced into eukaryotic cells, including but not restricted to, yeast cells and cultured plant cells.
- 1,3-Propanediol oxidoreductase (EC 1.1.1.202) is found in several species of bacteria. Often it is induced under anaerobic conditions in the presence of glycerol (Forage & Foster, 1982, J. Bacteriol. 149:413-419). This enzyme catalyzes the reversible formation of 3-hydroxypropionaldehyde and other hydroxyaldehydes from the corresponding diol. Physiologically the enzyme is thought to be primarily used in diol formation, when the aldehyde is needed as an electron acceptor at the expense of NADH (Johnson & Lin, J. Bacteriol. 169:2050-54).
- Organisms that contain 1,3-propanediol oxidoreductase typically are able to convert glycerol to 1,3-propanediol, though similar activities are found in other organisms.
- Bacterial species noted for the ability to convert glycerol to 1,3-propanediol include Klebsiella pneumoniae (Streekstra et al., 1987, Arch. Microbiol. 147:268-75), Klebsiella oxytoca (Homann et al., 1990, Appl. Microbiol. Biotechnol.
- Aldehyde dehydrogenases are extremely common in biological systems. Probing the E. coli genome database for homology shows that this organism alone contains at least seven putative enzymes of this type. They are so numerous and varied that even attempts to classify them all are complicated (e.g. Vasiliou et al., 1999, Pharmacogenetics 9:421-34). A discussion of all of the types and physiological roles of these enzymes is beyond the scope of this discussion. The choice of an appropriate aldehyde dehydrogenase for use in metabolic engineering should be done after evaluation of the substrate specificity of several candidates. Enzyme assays such as that described in Baldomá & Aguilar (1987, J. Biol. Chem. 262:13991-6) are useful for such diagnoses.
- Acyl-CoA transferases (EC 2.8.3.x) and acyl-CoA synthetases (EC 6.2.1.x) both catalyze the formation of thioesters of organic acids with coenzyme A.
- Acyl-CoA transferases such as OrfZ (also called HbcT) (Söhling and Gottschalk, 1996, J. Bacteriol 178:871-80) transfer the CoA moiety from a donor such as acetyl-CoA to a free organic acid, such as a fatty acid.
- Acyl-CoA synthetases such as AlkK (van Beilen et al., 1992, Mol. Microbiol. 6:3121-36) ligate free organic acid and free coenzyme A, deriving the energy for the reaction from ATP and leaving AMP and pyrophosphate as byproducts.
- a specific diol may not be converted to PHA at an acceptable rate in a specific organism. Improvements of this nature will generally involve mutagenesis and screening; the DNA sequence(s) to be improved are subjected to one or more rounds of mutagenesis followed by an assessment of improvements made.
- Mutagenesis can be implemented using any of a variety of ways known to those skilled in the art (e.g., error-prone PCR or cassette mutagenesis, passage through bacterial mutator strains, treatment with chemical mutagens), such as those described by Cadwell et al., 1992, PCR Methods and Applications 2:28-33; Erickson et al., 1993, Appl. Environ. Microbiol. 59:3858-62; Hermes et al., 1990, Proc. Natl. Acad. Sci.
- Screening for an improved diol-to-PHA pathway involves culturing a population of mutants generated as described above in such a way that cells improved in some property relating to the pathway can be selected readily.
- One embodiment is the selection for improved growth on the diol of interest. An organism deficient in uptake or utilization of a particular diol will not grow well with that diol as the sole carbon source. A pool of mutants can be inoculated into liquid medium or onto agar plates containing the diol as sole carbon source, along with all other nutrients necessary for growth of the organism in question, and cells able to grow may be readily isolated. Another embodiment is the selection of cells able to produce polymer when cultured in the presence of the diol.
- Plates can also serve to eliminate strains that cannot grow in the conditions it presents; for example, a cell that has gained via mutagenesis the ability to produce PHA from diol, but has lost an industrially important characteristic such as the ability to grow on minimal glucose medium, will not grow on plates containing diol and glucose, especially if it cannot grow on the diol as sole carbon source. Only the cells that can produce PHA from diol and can grow on minimal glucose in this case will appear as opaque colonies. PHA can be visualized within cells, especially on plates, by methods more sensitive than visual screening of untreated colonies, such as by staining with Nile red (as in, e.g., Spiekermann et al, 1999, Arch Microbiol. 171:73-80.). Methods such as those above may be repeated for several rounds to further optimize the diol-to-PHA pathway. Methods of screening are illustrated by, but not restricted to, the aspects of the discussion above, and other useful screening procedures will be apparent to those skilled in the art.
- any of the aforementioned embodiments it is possible to control the composition of the polymer produced by controlling the expression of the diol oxidoreductase and aldehyde dehydrogenase or by controlling the availability of the diol.
- Methods for modulation of gene expression (and thus enzyme activity) in various organisms are well-known to those skilled in the art.
- the rate of diol feed to the cultured cells can be controlled by various techniques well-known to those skilled in fermentation and cell culture.
- some or all of the genes can be integrated into the host chromosome and some or all provided on a plasmid.
- compatible plasmid systems can be used, for example, with several steps of the pathway encoded on one plasmid and the other steps encoded by a second plasmid. A combination of the two approaches may also be used.
- substrates that can be used to make PHAs in the context of the systems described herein include alcohols, preferably diols.
- suitable diols include 1,6-hexanediol, 1,5-pentanediol, 1,4-butanediol, 1,3-propanediol, 1,2-ethanediol, and 1,2-propanediol.
- diols are nontoxic to many microorganisms, in many cases even at high concentrations. They can be superior feedstocks for fermentation as compared to organic acids, which often become toxic at low concentrations to many microorganisms. Many diols are readily available and relatively inexpensive. For example, 1,4-butanediol had a global demand of about 1 billion pounds in 1995 and is very widely used for synthetic polymer production (Morgan, Chemistry & Industry , Mar. 3, 1997, pp. 166-8).
- Plasmid pMS33 contains aldH under the control of the trc promoter.
- E. coli DH5 ⁇ was transformed with pMS33 or pFS14, as a negative control.
- Plasmid pFS14 contains the Clostridium kluyveri 4hbD (4HB dehydrogenase) gene, as described in Söhling and Gottschalk (1996, J. Bacteriol. 178:871-80).
- DH5 ⁇ /pMS33 and DH5 ⁇ /pFS14 were grown at 37° C. with shaking in Luria-Bertani (LB; Difco; Detroit, Mich.) broth to an optical density (600 mn) of 0.5 and subsequently induced with 1 mM isopropyl- ⁇ -D-thiogalactopyranoside (IPTG). The incubation continued for 3 hours, after which the cells were removed from the medium by centrifugation (2000 g, 10 min.), washed in 0.1 M Tris (pH 8.0), centrifuged again, and resuspended in a volume of 0.1 M Tris (pH 8.0) roughly equal to the size of the cell pellet.
- LB Luria-Bertani
- IPTG isopropyl- ⁇ -D-thiogalactopyranoside
- Each sample was sonicated (XL sonicator, Heat Systems-Ultrasonics, Inc., Farmingdale, N.Y.) with a microtip in 3-mL aliquots on ice for 2 min. each at a 70% cycle with a one-second interval.
- the lysate was spun in a microcentrifuge at 14,000 g for 10 min. and the supernatant was collected and designated crude cell extract.
- the enzyme assays were conducted in a total volume of 1 mL containing 100 mM sodium glycine (pH 9.5), 1 mM 3-hydroxypropionaldehyde (3HPA), 1 mM NAD + or NADP + , 6 mM dithiothreitol (DTT), and a volume of crude cell extract containing 20-100 ⁇ g total protein.
- a baseline was established prior to adding 3HPA, which started the reaction.
- the activity given by the DH5 ⁇ /pFS14 extract was 0.00 U/mg when NAD + was used and 0.03 U/mg when NADP + was used.
- the activity given by the DH5 ⁇ /pMS33 extract was 1.89 U/mg when NAD + was used and 0.32 U/mg when NADP + was used.
- cells expressing the E. coli AldH protein gain the ability to convert 3HPA to 3-hydroxypropionic acid with either NAD + or NADP + as cofactor.
- the 4hbD gene was cloned by PCR using the plasmid pCK3 (Söhling & Gottschalk, 1996, J. Bacteriol. 178:871-80) as a template.
- the following oligonucleotide primers were used: 5′-CTCTGAATTCAAGGAGGAAAAAATATGAAGTTATTAAAATTGGC-3′ (4hbD 5′ EcoRI) 5′-TTTCTCTGAGCTCGGGATATTTAATGATTGTAGG-3′ (4hbD 3′ SacI)
- pTrcN is a derivative of pTrc99a (Pharmacia; Uppsala, Sweden); the modification that distinguishes pTrcN is the removal of the NcoI restriction site by digestion with NcoI, treatment with T4 DNA polymerase, and self-ligation.
- the aldH gene was cloned by PCR from the E. coli genome using the following oligonucleotide primers: 5′-GGTGGTACCTTAAGAGGAGGTTTTTATGAATTTTCATCACCTGGCTT-3′ (aldH 5′ Acc65I) 5′-GGTGCGGCCGCTCAGGCCTCCAGGCTTATCCA-3′ (aldH 3′ NotI)
- E. coli strain LS5218 obtained from the Yale E. coli Genetic Stock Center, New Haven, Conn., as strain CGSC 6966 was transformed with either of two plasmids, pFS76 or pFS77.
- pFS76 contains the 4HB dehydrogenase (gbd) gene from Ralstonia eutropha, as described in Valentin et al. (1995, Eur. J. Biochem. 227:43-60).
- Plasmid pFS77 contains the gbd gene as well as the E.
- aldH aldehyde dehydrogenase
- dhaT Klebsiella pneumoniae 1,3-propanediol oxidoreductase
- LS5218/pFS76 and LS5218/pFS77 were streaked onto minimal-medium plates containing 5 g/L of either 4HB (4-hydroxybutyrate, as the sodium salt) or 1,4-butanediol.
- the plate medium also contained, per liter: 15 g agar; 1 mmol MgSO 4 ; 10 mg thiamine; 25.5 mmol Na 2 HPO 4 ; 33.3 mmol K 2 HPO 4 ; 27.2 mmol KH 2 PO 4 ; 2.78 mg FeSO 4 .7H 2 O; 1.98 mg MnCl 2 .4H 2 O; 2.81 mg CoSO 4 .7H 2 O;0.17 mg CuCl 2 .2H 2 O; 1.67 mg CaCl 2 .2H 2 O; 0.29 mg ZnSO 4 .7H 2 O; 100 ⁇ g ampicillin; and 0.1 mmol IPTG.
- the plates were incubated overnight at 37° C.
- the gbd gene was amplified by PCR from the genome of R. eutropha H16 (obtained from the American Type Culture Collection, Rockville, Md., as strain ATCC 17699) using the following oligonucleotide primers: 5′-CCTGAATTCAGGAGGTTTTTATGGCGTTTA TCTACTATCTGACCCAC-3′ (gbd 5′ EcoRI) 5′-CCTGAGCTCCTACCTGCAAGTGCTCGCCGCTC-3′ (gbd 3′ SacI)
- the aldH-dhaT region was removed from pMS59 by digestion with NheI and HindIII. Plasmid pFS76 was digested with SpeI and HindIII. NheI and SpeI form compatible sticky ends. The aldH-dhaT fragment from pMS59 and the large fragment of pFS76 were ligated together to give pFS77, containing the gbd, aldH, and dhaT genes, all under control of the trc promoter.
- Escherichia coli strain LS5218 (CGSC 6966) was transformed with either of two plasmids, pFS30 or pMS60.
- pFS30 contains the Ralstonia eutropha PHA synthase (phaC) gene and the Clostridium kluyveri 4HB-CoA transferase (hbcT) gene, both under control of the trc promoter.
- pMS60 contains the aldH and dhaT genes along with the two genes in pFS30, all under control of the trc promoter. The objective of the experiment was to determine whether the addition of the aldH and dhaT genes would be beneficial to the conversion of 1,4-butanediol to 4HB in the PHA polymer.
- Each strain was grown in LB broth supplemented with 100 ⁇ g/mL ampicillin overnight at 37° C. with shaking at 250 rpm. The cells were then removed from the medium by centrifugation (2000 g, 10 min.) and resuspended in 100 mL of a medium containing, per liter: 2.5 g LB powder; 50 mmol potassium phosphate, pH 7.0; 2 g glucose; 5 g 1,4-butanediol; 100 ⁇ g ampicillin; and 0.1 mmol IPTG. These incubations were at 30° C. with shaking at 250 rpm for 25 hours.
- the cells from one-quarter of the volume of the flask were centrifuged as above, washed with water, centrifuged again, and lyophilized. About 20 mg of lyophilized cell mass from each flask was subjected to simultaneous extraction and butanolysis at 110° C. for 3 hours in 2 mL of a mixture containing (by volume) 90% 1-butanol and 10% concentrated hydrochloric acid, with 2 mg/mL benzoic acid added as an internal standard. The water-soluble components of the resulting mixture were removed by extraction with 3 mL water.
- the organic phase (1 ⁇ L at a split ratio of 1:50 at an overall flow rate of 2 mL/min) was analyzed on an SPB-1 fused silica capillary GC column (30 m; 0.32 mm ID; 0.25 ⁇ m film; Supelco; Bellefonte, Pa.) with the following temperature profile: 80° C., 2 min; 10° C. per min. to 250° C.; 250° C., 2 min.
- the standard used to test for the presence of 4-hydroxybutyrate units in the polymer was gamma-butyrolactone (Aldrich Chemical Co.; Milwaukee, Wis.).
- Strain LS5218/pFS30 reached an optical density (600 nm) of 3.9 and had accumulated poly-4HB to 3.3% of the dry cell weight, while strain LS5218/pMS60 reached an optical density (600 nm) of 6.5 and had accumulated poly-4HB to 12.3% of the dry cell weight.
- expression of the aldH and dhaT genes is sufficient to increase the ability of E. coli LS5218 to synthesize poly-4HB from 1,4-butanediol.
- the plasmid pFS16 was constructed by ligating the Clostridium kluyveri orfZ (also called hbcT) PCR product to pTrcN.
- the orfZ gene was amplified by PCR from plasmid pCK3 (Söhling and Gottschalk, 1996, J. Bacteriol 178:871-80) using the following oligonucleotide primers: 5′-TCCCCTAGGATTCAGGAGGTTTTTATGGAGTGGGAA GAGATATATAAAG-3′ (orfZ 5′ AvrII) 5′-CCTTAAGTCGACAAATTCTAAAATCTCTTTTTAAATTC-3′ (orfZ 3′ SalI)
- the resulting PCR product was digested with AvrII and SalI and ligated to pTrcN that had been digested with XbaI (which is compatible with AvrII) and SalI to form pFS16.
- the plasmid pFS30 was derived from pFS16 by adding the Ralstonia eutropha PHA synthase (phaC) gene.
- the plasmid pAeT414 was digested with XmaI and StuI so that the R. eutropha promoter and the structural phaC gene were present on one fragment.
- pFS16 was cut with BamHI, treated with T4 DNA polymerase to create blunt ends, then digested with XmaI. The two DNA fragments thus obtained were ligated together to form pFS30.
- the aldH gene was removed from pMS33 by digestion with SpeI and BglII.
- Plasmid pTC42 (Skraly et al., 1998, Appl. Environ. Microbiol. 64:98-105), which contains the Klebsiella pneumoniae dhaT gene under the control of the trc promoter, was digested with NheI and BglII. SpeI and NheI form compatible sticky ends.
- the aldH-containing fragment of pMS33 and the large fragment of pTC42 were ligated together to form pMS59.
- the aldH-dhaT region was isolated from pMS59 by digestion with SpeI, followed by treatment with the Klenow fragment of DNA polymerase I and subsequent digestion with MfeI. This fragment had one blunt end and one sticky end compatible with EcoRI-generated sticky ends.
- pFS30 was digested with XmaI, followed by treatment with the Klenow fragment of DNA polymerase I and subsequent digestion with EcoRI. The large fragment of pFS30 and the aldH-dhaT-containing fragment of pMS59 were ligated together to form pMS60.
- E. coli strain MBX1493 is a poly(3HB-co-4HB) producing strain with the C. kluyveri orjZ (also called hbcT) gene (Söhling & Gottschalk, 1996, J. Bacteriol. 178:871-80) integrated into its chromosome. It was derived from strain MBX1335, a PHB-producing strain with the phaA, phaB, and phaC genes integrated into its chromosome. MBX1335 was itself derived from MBX820 (see PCT WO 00/011188 by Metabolix) by bacteriophage P1 transduction of the phaA, phaB, and phaC genes into strain LS5218.
- Strain MBX1493 was transformed with four plasmids in separate procedures: pTrcN, pTC42, pMS33, and pMS59. These plasmids contain, under control of the trc promoter, the following genes, respectively: none, dhaT only, aldH only, both aldH and dhaT. Each of these strains was grown in 3 mL LB supplemented with 100 ⁇ g/mL ampicillin at 37° C. with shaking overnight.
- a volume of 1 mL of each of these cultures was used as an inoculum into 50 mL of a medium containing, per liter: 1 mmol MgSO 4 ; 10 mg thiamine; 25.5 mmol Na 2 HPO 4 ; 33.3 mmol K 2 HPO 4 ; 27.2 mmol KH 2 PO 4 ; 2.78 mg FeSO 4 .7H 2 O; 1.98 mg MnCl 2 .4H 2 O; 2.81 mg CoSO 4 .7H 2 O; 0.17 mg CuCl 2 .2H 2 O; 1.67 mg CaCl 2 .2H 2 O; 0.29 mg ZnSO 4 .7H 2 O; 10 g glucose; 5 g 4-hydroxybutyrate or 10 g 1,4-butanediol; 100 ⁇ g ampicillin; 25 ⁇ g chloramphenicol; and 0.01 mmol IPTG.
- Escherichia coli strain LS5218 (CGSC 6966) was transformed with either of two plasmids, pFS30 or pMS60.
- the objective of the experiment was to determine whether the addition of the aldH and dhaT genes would be beneficial to the conversion of 1,3-propanediol to 3HP.
- Each strain was grown in LB broth supplemented with 100 ⁇ g/mL ampicillin overnight at 37° C. with shaking at 250 rpm. The cells were then removed from the medium by centrifugation (2000 g, 10 min.) and resuspended in 50 mL of a medium containing, per liter: 2.5 g LB powder; 50 mmol potassium phosphate, pH 7.0; 5 g glucose; 0 or 10 g 1,3-propanediol; 100 ⁇ g ampicillin; and 0.1 mmol IPTG. These incubations were at 30° C. with shaking at 250 rpm for 25 hours.
- the cells were removed from the medium by centrifugation as described above, washed with water, centrifuged again, lyophilized, and analyzed for PHA content and composition by GC.
- the standard used to test for the presence of 3-hydroxypropionate units in the polymer was beta-propiolactone (Aldrich Chemical Co.; Milwaukee, Wis.).
- strains LS5218/pFS30 and LS5218/pMS60 reached optical densities (600 nm) of 4.6 and 8.2, respectively.
- strain LS5218/pFS30 reached an optical density (600 nm) of 5.2 and did not accumulate poly-3HP to a detectable level
- strain LS5218/pMS60 reached an optical density (600 nm) of 6.6 and had accumulated poly-3HP to 5.0% of the dry cell weight.
- expression of the aldH and dhaT genes is sufficient to increase the ability of E. coli LS5218 to synthesize poly-3HP from 1,3-propanediol.
- Strain MBX1493 was transformed with four plasmids in separate procedures: pTrcN, pTC42, pMS33, and pMS59. Each of these strains was grown in 100 mL LB supplemented with 100 ⁇ g/mL ampicillin at 37° C. with shaking overnight. The cells were decanted from each flask, and the residual liquid was retained.
- the cells were then removed from this medium by centrifugation (2000 g, 10 min.), and they were lyophilized and analyzed for PHA content and composition by GC.
- Table 2 shows the composition of the polymers made by these strains and the final optical densities (600 nm) of the cultures.
- each strain synthesized only PHB In the absence of 1,3-propanediol, each strain synthesized only PHB. When fed 1,3-propanediol, only the pMS59-containing cells, that is, the cells expressing both aldH and dhaT, achieved a significant level of 3HP incorporation into the polymer. The cells containing pMS33, or aldH alone, do accomplish 3HP incorporation, but to only a small extent. Thus the aldH-dhaT pathway was shown to enable the conversion of 1,3-propanediol to 3HP.
- the cells containing the dhaT gene made less total polymer when 1,3-propanediol was present, and this is most likely due to the toxicity of 3-hydroxypropionaldehyde. Increasing the ratio of aldH to dhaT expression and/or reducing 1,3-propanediol concentration should subdue this phenomenon.
- Strain MBX1668 which has the aldH and dhaT genes integrated into its chromosome as an operon along with the tetracycline resistance marker from Tn10, was transformed with either of two plasmids: pFS73 or pMS92.
- the plasmid pFS73 is the same as pFS30 described in previous examples except that the ampicillin resistance marker has been replaced with the kanamycin resistance marker from pACYC177 (GenBank Accession No. X06402).
- the plasmid pMS92 is derived from pFS73, the orfZ gene having been replaced with the alkK gene from Pseudomonas oleovorans (van Beilen et al., 1992, Mol. Microbiol. 6:3121-36).
- Each of these strains was grown in 3 mL LB supplemented with 50 ⁇ g/mL kanamycin and 10 ⁇ g/mL tetracycline at 37° C. with shaking overnight.
- One milliliter of each culture was added as an inoculum to a 200-mL square bottle.
- Each bottle held 50 mL of a medium containing, per liter: 0.1 g casamino acids; 5 mmol MgSO 4 ; 10 mg thiamine; 25.5 mmol Na 2 HPO 4 ; 33.3 mmol K 2 HPO 4 ; 27.2 mmol KH 2 PO 4 ; 2.78 mg FeSO 4 .7H 2 O; 1.98 mg MnCl 2 .4H 2 O; 2.81 mg CoSO 4 .7H 2 O; 0.17 mg CuCl 2 .2H 2 O; 1.67 mg CaCl 2 .2H 2 O; 0.29 mg ZnSO 4 .7H 2 O; 10 g glucose; 10 g 1,4-butanediol; 50 ⁇ g kanamycin; and 10 ⁇ g tetracycline.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Biological Depolymerization Polymers (AREA)
- Polyesters Or Polycarbonates (AREA)
Abstract
Recombinant processes are provided whereby additional genes are introduced into E. coli which have been genetically engineered to produce PHA so that the improved strains produce PHA homopolymers and copolymers directly from diols. In preferred embodiments, PHAs containing 4-hydroxybutyrate monomers are produced directly from 1,4-butanediol; PHAs containing 5-hydroxyvalerate are produced from 1,5-pentanediol; PHAs containing 6-hydroxyhexanoate (6HH) are produced from 1,6-hexanediol; PHAs containing 3-hydroxypropionate are produced from 1,3-propanediol; PHAs containing 2-hydroxypropionate (lactate) are produced from 1,2-propanediol (propylene glycol); PHAs containing 2-hydroxyethanoate (glycolate) are produced from 1,2-ethanediol (ethylene glycol). Genes encoding these same enzyme activities can be introduced or their expression amplified in wild type PHA producers to improve the production of PHA homopolymers and copolymers directly from diol and other alcohol feedstocks. The PHA polymers are readily recovered and industrially useful as polymers or as starting materials for a range of chemical intermediates.
Description
- Priority is claimed to U.S. Provisional Application Serial No. 60/219,995 filed on Jul. 21, 2000.
- This invention is generally in the field of production of polyhydroxyalkanoates (PHAs) by genetic engineering of bacteria.
- Synthesis of PHA polymers containing the monomer 4-hydroxybutyrate (4HB), such as poly(3-hydroxybutyrate-co-4-hydroxybutyrate) (PHB4HB) (Doi, 1995,Macromol Symp. 98:585-99) or 4-hydroxyvalerate and 4-hydroxyhexanoate containing PHA polyesters have been described, for example, in Valentin et al., 1992, Appl. Microbiol. Biotechnol. 36:507-14 and Valentin et al., 1994, Appl. Microbiol. Biotechnol. 40:710-16. Production of PHB4HB, for example, has been accomplished by feeding glucose and 4HB or a substrate that is converted to 4-hydroxybutyrate to Ralstonia eutropha (Kunioka, et al., 1988, Polym. Commun. 29:174; Doi, et al., 1990, Int. J. Biol. Macromol. 12:106; Nakamura, et al., 1992, Macromolecules 25:423), to Alcaligenes latus (Hiramitsu, et al., 1993, Biotechnol. Lett. 15:461), to Pseudomonas acidovorans (Kimura, et al., 1992, Biotechnol. Lett. 14:445), and to Comamonas acidovorans (Saito & Doi, 1994, Int. J. Biol. Macromol. 16:18). Substrates that are converted to 4HB include 1,4-butanediol, 1,6-hexanediol, 1,8-octanediol, 1,10-decanediol, 1,12-dodecanediol and gamma-butyrolactone. The PHB4HB copolymers can be produced with a range of monomer compositions which provide a range of polymer properties. In particular, as the amount of 4HB increases above 15 wt. %, the melting temperature (Tm) decreases below 130° C. and the elongation to break increases above 400% (Saito, et al., 1996, Polym. Int. 39:169).
- It would be highly advantageous, however, to develop more cost effective ways of producing PHAs containing 4HB by biological systems. For economic production of PHA, several factors are critical, including substrate costs, fermentation time, and efficiency of downstream processing. A general characteristic of the wild type PHA-producing bacteria is that their growth rate is low, they are often difficult to break open and their amenity to genetic engineering is limited. Therefore, it would be desirable to develop transgenic organisms that provide improved economics of PHA production.
- The production of the copolymer PHB4HB in recombinantE. coli has been described (e.g., PCT WO 00/011188 by Huisman et al.; PCT WO 98/39453 by Hein et al.). A range of novel biologically produced 4HB polymers produced in recombinant E. coli have been described by Skraly and Peoples (e.g., PCT WO 99/61624). In these studies only the Huisman reference demonstrated the incorporation of small amounts of 4HB co-monomer from 1,4-butanediol. It would be highly advantageous to develop genetically engineered systems capable of the production of a range of 4HB copolymers and poly-4HB homopolymer using 1,4-butanediol as the source of the 4HB monomer.
- It is therefore an object of the present invention to provide improved recombinant systems and methods for the production of PHAs, such as PHAs containing the 4HB monomer, using a variety of simple sugars and alcohols as substrates.
- Recombinant processes are provided whereby additional genes are introduced intoE. coli which have been genetically engineered to produce PHA so that the improved strains produce PHA homopolymers and copolymers directly from diols. In preferred embodiments, PHAs containing 4-hydroxybutyrate (4HB) monomers are produced directly from 1,4-butanediol; PHAs containing 5-hydroxyvalerate (5HV) are produced from 1,5-pentanediol; PHAs containing 6-hydroxyhexanoate (6HH) are produced from 1,6-hexanediol; PHAs containing 3-hydroxypropionate (3HP) are produced from 1,3-propanediol (also called propylene glycol); PHAs containing 2-hydroxypropionate (2HP, lactate) are produced from 1,2-propanediol (propylene glycol); PHAs containing 2-hydroxyethanoate (2HE, glycolate) are produced from 1,2-ethanediol (ethylene glycol). Genes encoding these same enzyme activities can be introduced or their expression amplified in wild type PHA producers to improve the production of PHA homopolymers and copolymers directly from diol and other alcohol feedstocks. The PHA polymers are readily recovered and industrially useful as polymers or as starting materials for a range of chemical intermediates.
- FIG. 1 illustrates the pathway from 1,4-butanediol to 4-hydroxybutyryl-CoA that is employed in one embodiment.
- Processes are provided whereby additional genes are introduced into microorganisms which have been genetically engineered to produce PHA so that the improved strains produce PHA homopolymers and copolymers directly from simple alcohol and sugar substrates. These processes are based on recombinant bacteria e.g.,Escherichia coli as a production organism and PHA biosynthetic genes from PHA-producing microbes such as Ralstonia eutropha or Alcaligenes latus although many other sources of PHA genes are now known (Madison & Huisman, 1999, Microbiol. & Molecular Biology Reviews, 63:21-53). Recombinant E. coli has many advantages over the wild type PHA producing organisms including ease of genetic manipulation, complete availability of the genome sequence, fast growth rate, flexibility of growth substrates and ready lysis.
- Organisms to be Engineered
- In one embodiment, genes for the entire pathway illustrated in FIG. 1 are introduced into the production organism. An organism that does not naturally produce PHAs, such asEscherichia coli, may be used. A number of recombinant E. coli PHB production systems have been described (Madison & Huisman, 1999, Microbiology & Molecular Biology Reviews, 63:21-53). The genes encoding a diol oxidoreductase and aldehyde dehydrogenase are introduced into this host. In the case of 1,4-butanediol, the diol oxidoreductase converts the substrate to 4-hydroxybutyraldehyde, which is then converted to 4-hydroxybutyrate by the aldehyde dehydrogenase. In the case of 1,3-propanediol, the diol oxidoreductase converts the substrate to 3-hydroxypropionaldehyde, which is then converted to 3-hydroxypropionate by the aldehyde dehydrogenase. Other diols may be treated in an analogous way. In some instances incorporation into PHA of a hydroxyacid that is two carbons shorter than the diol feedstock may occur. This is due to endogenous catabolism resembling that of the beta-oxidation pathway of fatty acid catabolism. For example, 4HB units, or both 4HB and 6HH units, may be produced in the polymer as a result of feeding 1,6-hexanediol. Optionally an exogenous acyl-CoA transferase or acyl-CoA synthetase may be included to facilitate activation of the hydroxyacid with coenzyme A. The activated monomer may then be incorporated into PHA by the action of an appropriate PHA synthase present in the production host. The enzyme activities provide a system for the synthesis in the production host of a polymer containing one or more monomer types, depending upon the diol feedstocks.
- It is often very useful to synthesize copolymers containing monomers like those mentioned above and 3HB. In this case, the production host will also contain the β-ketothiolase and acetoacetyl-CoA reductase genes, the products of which convert acetyl-CoA to 3HB-CoA. Acetyl-CoA may be derived from the diol or from another carbon source such as a sugar. Both 3HB-CoA and hydroxyacyl-CoAs such as those mentioned above can be accepted by various PHA synthases such as the one expressed in the recombinant host, and therefore copolymers of PHB are synthesized by the recombinant host. Whatever the desired PHA composition, the diol can be fed to the cells either during growth or after a separate growth phase, either alone or in combination with at least one other feedstock, such as a sugar, and PHA is accumulated within the cells.
- In another embodiment, a recombinant organism that naturally contains at least part of the pathway shown in FIG. 1 can be used. In this embodiment one or more of the activities discussed above (diol oxidoreductase, aldehyde dehydrogenase, acyl-CoA transferase or acyl-CoA synthetase, β-ketothiolase, PHA synthase, and acetoacetyl-CoA reductase) can be derived from the endogenous machinery of the host. For example, only diol oxidoreductase and aldehyde dehydrogenase might be expressed inR. eutropha, a natural PHA-producing organism, to augment its ability to convert 1,4-butanediol to 4HB, and the natural ability of the host may be relied upon to accomplish the rest of the necessary metabolic steps. Many natural PHA-producing organisms are well-known to those skilled in the art (Braunegg et al. 1998, J. Biotechnology 65:127-61). If the host is not capable of PHA production, a PHA synthase or an entire PHB biosynthetic pathway and optionally an exogenous acyl-CoA transferase or acyl-CoA synthetase may be introduced into this organism to enable PHA production. Techniques for doing this are well known in the art (for example, Dennis et al., 1998, J. Biotechnology 64:177-86). Here also, the diol can be fed to the cells either during growth or after a separate growth phase, either alone or in combination with at least one other feedstock, such as a sugar, and PHA is accumulated within the cells.
- The implementation of the production of PHAs with diol feedstocks is not limited to bacteria as described in the examples. The same genes may be introduced into eukaryotic cells, including but not restricted to, yeast cells and cultured plant cells.
- Genes for Utilization of Substrates
- Genes and techniques for developing recombinant PHA producers suitable for use as described herein are generally known to those skilled in the art (Madison & Huisman, 1999,Microbiology and Molecular Biology Reviews, 63:21-53; PCT WO 99/14313). Because all of the genes necessary to implement the production of PHAs from feedstocks such as diols and sugars have been cloned and are available in genetically manipulatable form, any combination of plasmid-borne and integrated genes may be used, and the implementation of this pathway is therefore not restricted to the schemes outlined herein. Many different implementations will be apparent to those skilled in the art.
- 1,3-Propanediol oxidoreductase (EC 1.1.1.202) is found in several species of bacteria. Often it is induced under anaerobic conditions in the presence of glycerol (Forage & Foster, 1982,J. Bacteriol. 149:413-419). This enzyme catalyzes the reversible formation of 3-hydroxypropionaldehyde and other hydroxyaldehydes from the corresponding diol. Physiologically the enzyme is thought to be primarily used in diol formation, when the aldehyde is needed as an electron acceptor at the expense of NADH (Johnson & Lin, J. Bacteriol. 169:2050-54). Organisms that contain 1,3-propanediol oxidoreductase typically are able to convert glycerol to 1,3-propanediol, though similar activities are found in other organisms. Bacterial species noted for the ability to convert glycerol to 1,3-propanediol include Klebsiella pneumoniae (Streekstra et al., 1987, Arch. Microbiol. 147:268-75), Klebsiella oxytoca (Homann et al., 1990, Appl. Microbiol. Biotechnol. 33:121-26), Klebsiella planticola (Id.) and Citrobacter freundii (Boenigk et al., 1993, Appl. Microbiol. Biotechnol. 38:453-57) although many other examples are generally known.
- Aldehyde dehydrogenases are extremely common in biological systems. Probing theE. coli genome database for homology shows that this organism alone contains at least seven putative enzymes of this type. They are so numerous and varied that even attempts to classify them all are complicated (e.g. Vasiliou et al., 1999, Pharmacogenetics 9:421-34). A discussion of all of the types and physiological roles of these enzymes is beyond the scope of this discussion. The choice of an appropriate aldehyde dehydrogenase for use in metabolic engineering should be done after evaluation of the substrate specificity of several candidates. Enzyme assays such as that described in Baldomá & Aguilar (1987, J. Biol. Chem. 262:13991-6) are useful for such diagnoses.
- Acyl-CoA transferases (EC 2.8.3.x) and acyl-CoA synthetases (EC 6.2.1.x) both catalyze the formation of thioesters of organic acids with coenzyme A. Acyl-CoA transferases, such as OrfZ (also called HbcT) (Söhling and Gottschalk, 1996,J. Bacteriol 178:871-80) transfer the CoA moiety from a donor such as acetyl-CoA to a free organic acid, such as a fatty acid. Acyl-CoA synthetases such as AlkK (van Beilen et al., 1992, Mol. Microbiol. 6:3121-36) ligate free organic acid and free coenzyme A, deriving the energy for the reaction from ATP and leaving AMP and pyrophosphate as byproducts.
- Improvements in the Enzymes in the Pathway
- It may be advantageous to improve the specific activity or substrate specificity of the enzymes in the diol-to-PHA pathway described herein. For example, a specific diol may not be converted to PHA at an acceptable rate in a specific organism. Improvements of this nature will generally involve mutagenesis and screening; the DNA sequence(s) to be improved are subjected to one or more rounds of mutagenesis followed by an assessment of improvements made.
- Mutagenesis can be implemented using any of a variety of ways known to those skilled in the art (e.g., error-prone PCR or cassette mutagenesis, passage through bacterial mutator strains, treatment with chemical mutagens), such as those described by Cadwell et al., 1992,PCR Methods and Applications 2:28-33; Erickson et al., 1993, Appl. Environ. Microbiol. 59:3858-62; Hermes et al., 1990, Proc. Natl. Acad. Sci. USA 87:696-700; Ho et al., 1989, Gene 77:51-59; Kellog et al., 1981, Science 214:1133-35; Reidhaar-Olson et al., 1988, Science 241:53-57; Stemmer, 1994, Nature 370:389-91; and Stemmer, 1994, Proc. Natl. Acad. Sci. USA 91:10747-51.
- Screening for an improved diol-to-PHA pathway involves culturing a population of mutants generated as described above in such a way that cells improved in some property relating to the pathway can be selected readily. One embodiment is the selection for improved growth on the diol of interest. An organism deficient in uptake or utilization of a particular diol will not grow well with that diol as the sole carbon source. A pool of mutants can be inoculated into liquid medium or onto agar plates containing the diol as sole carbon source, along with all other nutrients necessary for growth of the organism in question, and cells able to grow may be readily isolated. Another embodiment is the selection of cells able to produce polymer when cultured in the presence of the diol. If an organism is unable to convert the diol at a significant rate to a monomer precursor that can subsequently be polymerized, plating that organism on agar containing the diol as the sole carbon source (other than carbon contained in any complex supplements added, such as yeast extract) will yield cells with little or no PHA content. Culturing a pool of mutants on such a plate can identify strains that have gained the ability to convert the diol to polymerizable intermediates. These cells will appear more opaque and white than the non-PHA-producing cells. Alternatively, another carbon source such as glucose may be added if the cells to be screened cannot synthesize polymer from that carbon source. Plates can also serve to eliminate strains that cannot grow in the conditions it presents; for example, a cell that has gained via mutagenesis the ability to produce PHA from diol, but has lost an industrially important characteristic such as the ability to grow on minimal glucose medium, will not grow on plates containing diol and glucose, especially if it cannot grow on the diol as sole carbon source. Only the cells that can produce PHA from diol and can grow on minimal glucose in this case will appear as opaque colonies. PHA can be visualized within cells, especially on plates, by methods more sensitive than visual screening of untreated colonies, such as by staining with Nile red (as in, e.g., Spiekermann et al, 1999,Arch Microbiol. 171:73-80.). Methods such as those above may be repeated for several rounds to further optimize the diol-to-PHA pathway. Methods of screening are illustrated by, but not restricted to, the aspects of the discussion above, and other useful screening procedures will be apparent to those skilled in the art.
- Regulation of Expression
- In any of the aforementioned embodiments, it is possible to control the composition of the polymer produced by controlling the expression of the diol oxidoreductase and aldehyde dehydrogenase or by controlling the availability of the diol. The higher the activities of diol oxidoreductase and aldehyde dehydrogenase, the more activated monomer will be derived as a result of their activities, up to the point where another factor such as substrate availability or an enzyme activity downstream of these becomes limiting. Methods for modulation of gene expression (and thus enzyme activity) in various organisms are well-known to those skilled in the art. The rate of diol feed to the cultured cells can be controlled by various techniques well-known to those skilled in fermentation and cell culture.
- In the case of some microorganisms, some or all of the genes can be integrated into the host chromosome and some or all provided on a plasmid. In some cases, compatible plasmid systems can be used, for example, with several steps of the pathway encoded on one plasmid and the other steps encoded by a second plasmid. A combination of the two approaches may also be used.
- Substrates
- As discussed above, substrates that can be used to make PHAs in the context of the systems described herein include alcohols, preferably diols. Examples of suitable diols include 1,6-hexanediol, 1,5-pentanediol, 1,4-butanediol, 1,3-propanediol, 1,2-ethanediol, and 1,2-propanediol.
- These diols are nontoxic to many microorganisms, in many cases even at high concentrations. They can be superior feedstocks for fermentation as compared to organic acids, which often become toxic at low concentrations to many microorganisms. Many diols are readily available and relatively inexpensive. For example, 1,4-butanediol had a global demand of about 1 billion pounds in 1995 and is very widely used for synthetic polymer production (Morgan,Chemistry & Industry, Mar. 3, 1997, pp. 166-8).
- The present invention will be further understood by reference to the following non-limiting examples.
- On the basis of its homology with other aldehyde dehydrogenases, the aldH gene was cloned by PCR from theE. coli genome. Plasmid pMS33 contains aldH under the control of the trc promoter. E. coli DH5α was transformed with pMS33 or pFS14, as a negative control. Plasmid pFS14 contains the Clostridium kluyveri 4hbD (4HB dehydrogenase) gene, as described in Söhling and Gottschalk (1996, J. Bacteriol. 178:871-80).
- DH5α/pMS33 and DH5α/pFS14 were grown at 37° C. with shaking in Luria-Bertani (LB; Difco; Detroit, Mich.) broth to an optical density (600 mn) of 0.5 and subsequently induced with 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG). The incubation continued for 3 hours, after which the cells were removed from the medium by centrifugation (2000 g, 10 min.), washed in 0.1 M Tris (pH 8.0), centrifuged again, and resuspended in a volume of 0.1 M Tris (pH 8.0) roughly equal to the size of the cell pellet. Each sample was sonicated (XL sonicator, Heat Systems-Ultrasonics, Inc., Farmingdale, N.Y.) with a microtip in 3-mL aliquots on ice for 2 min. each at a 70% cycle with a one-second interval. The lysate was spun in a microcentrifuge at 14,000 g for 10 min. and the supernatant was collected and designated crude cell extract.
- The enzyme assays were conducted in a total volume of 1 mL containing 100 mM sodium glycine (pH 9.5), 1 mM 3-hydroxypropionaldehyde (3HPA), 1 mM NAD+ or NADP+, 6 mM dithiothreitol (DTT), and a volume of crude cell extract containing 20-100 μg total protein. A baseline was established prior to adding 3HPA, which started the reaction. The activity given by the DH5α/pFS14 extract was 0.00 U/mg when NAD+ was used and 0.03 U/mg when NADP+ was used. The activity given by the DH5α/pMS33 extract was 1.89 U/mg when NAD+ was used and 0.32 U/mg when NADP+ was used. Thus cells expressing the E. coli AldH protein gain the ability to convert 3HPA to 3-hydroxypropionic acid with either NAD+ or NADP+ as cofactor.
- Construction of pFS14
- The 4hbD gene was cloned by PCR using the plasmid pCK3 (Söhling & Gottschalk, 1996,J. Bacteriol. 178:871-80) as a template. The following oligonucleotide primers were used:
5′-CTCTGAATTCAAGGAGGAAAAAATATGAAGTTATTAAAATTGGC-3′ (4hbD 5′ EcoRI) 5′-TTTCTCTGAGCTCGGGATATTTAATGATTGTAGG-3′ (4hbD 3′ SacI) - The resulting PCR product was digested with EcoRI and SacI and ligated to plasmid pTrcN that had been digested with the same enzymes. pTrcN is a derivative of pTrc99a (Pharmacia; Uppsala, Sweden); the modification that distinguishes pTrcN is the removal of the NcoI restriction site by digestion with NcoI, treatment with T4 DNA polymerase, and self-ligation.
- Construction of pMS33
- On the basis of its homology with other aldehyde dehydrogenases, the aldH gene was cloned by PCR from theE. coli genome using the following oligonucleotide primers:
5′-GGTGGTACCTTAAGAGGAGGTTTTTATGAATTTTCATCACCTGGCTT-3′ (aldH 5′ Acc65I) 5′-GGTGCGGCCGCTCAGGCCTCCAGGCTTATCCA-3′ (aldH 3′ NotI) - The resulting PCR product was digested with Acc65I and NotI and ligated to pSE380 (Invitrogen; Carlsbad, Calif.) that had been digested with the same enzymes to form pMS33.
-
- LS5218/pFS76 and LS5218/pFS77 were streaked onto minimal-medium plates containing 5 g/L of either 4HB (4-hydroxybutyrate, as the sodium salt) or 1,4-butanediol. The plate medium also contained, per liter: 15 g agar; 1 mmol MgSO4; 10 mg thiamine; 25.5 mmol Na2HPO4; 33.3 mmol K2HPO4; 27.2 mmol KH2PO4; 2.78 mg FeSO4.7H2O; 1.98 mg MnCl2.4H2O; 2.81 mg CoSO4.7H2O;0.17 mg CuCl2.2H2O; 1.67 mg CaCl2.2H2O; 0.29 mg ZnSO4.7H2O; 100 μg ampicillin; and 0.1 mmol IPTG. The plates were incubated overnight at 37° C. Both strains grew on the 4HB plate, but only LS5218/pFS77 grew on the 1,4-butanediol plate. Therefore, it was shown that the pathway consisting of the gbd, aldH, and dhaT genes is sufficient for growth of E. coli LS5218 with 1,4-butanediol as the sole carbon source.
- Construction of pFS76
- The gbd gene was amplified by PCR from the genome ofR. eutropha H16 (obtained from the American Type Culture Collection, Rockville, Md., as strain ATCC 17699) using the following oligonucleotide primers:
5′-CCTGAATTCAGGAGGTTTTTATGGCGTTTA TCTACTATCTGACCCAC-3′ (gbd 5′ EcoRI) 5′-CCTGAGCTCCTACCTGCAAGTGCTCGCCGCTC-3′ (gbd 3′ SacI) - The resulting PCR product was digested with EcoRI and SacI and ligated to pSE380 (Invitrogen; Carlsbad, Calif.) that had been digested with the same enzymes to form pFS76.
- Construction of pFS77
- The aldH-dhaT region was removed from pMS59 by digestion with NheI and HindIII. Plasmid pFS76 was digested with SpeI and HindIII. NheI and SpeI form compatible sticky ends. The aldH-dhaT fragment from pMS59 and the large fragment of pFS76 were ligated together to give pFS77, containing the gbd, aldH, and dhaT genes, all under control of the trc promoter.
-
- Each strain was grown in LB broth supplemented with 100 μg/mL ampicillin overnight at 37° C. with shaking at 250 rpm. The cells were then removed from the medium by centrifugation (2000 g, 10 min.) and resuspended in 100 mL of a medium containing, per liter: 2.5 g LB powder; 50 mmol potassium phosphate, pH 7.0; 2 g glucose; 5 g 1,4-butanediol; 100 μg ampicillin; and 0.1 mmol IPTG. These incubations were at 30° C. with shaking at 250 rpm for 25 hours. The cells from one-quarter of the volume of the flask were centrifuged as above, washed with water, centrifuged again, and lyophilized. About 20 mg of lyophilized cell mass from each flask was subjected to simultaneous extraction and butanolysis at 110° C. for 3 hours in 2 mL of a mixture containing (by volume) 90% 1-butanol and 10% concentrated hydrochloric acid, with 2 mg/mL benzoic acid added as an internal standard. The water-soluble components of the resulting mixture were removed by extraction with 3 mL water. The organic phase (1 μL at a split ratio of 1:50 at an overall flow rate of 2 mL/min) was analyzed on an SPB-1 fused silica capillary GC column (30 m; 0.32 mm ID; 0.25 μm film; Supelco; Bellefonte, Pa.) with the following temperature profile: 80° C., 2 min; 10° C. per min. to 250° C.; 250° C., 2 min. The standard used to test for the presence of 4-hydroxybutyrate units in the polymer was gamma-butyrolactone (Aldrich Chemical Co.; Milwaukee, Wis.).
- Strain LS5218/pFS30 reached an optical density (600 nm) of 3.9 and had accumulated poly-4HB to 3.3% of the dry cell weight, while strain LS5218/pMS60 reached an optical density (600 nm) of 6.5 and had accumulated poly-4HB to 12.3% of the dry cell weight. Thus expression of the aldH and dhaT genes is sufficient to increase the ability ofE. coli LS5218 to synthesize poly-4HB from 1,4-butanediol.
- Construction of pFS16
- The plasmid pFS16 was constructed by ligating theClostridium kluyveri orfZ (also called hbcT) PCR product to pTrcN. The orfZ gene was amplified by PCR from plasmid pCK3 (Söhling and Gottschalk, 1996, J. Bacteriol 178:871-80) using the following oligonucleotide primers:
5′-TCCCCTAGGATTCAGGAGGTTTTTATGGAGTGGGAA GAGATATATAAAG-3′ (orfZ 5′ AvrII) 5′-CCTTAAGTCGACAAATTCTAAAATCTCTTTTTAAATTC-3′ (orfZ 3′ SalI) - The resulting PCR product was digested with AvrII and SalI and ligated to pTrcN that had been digested with XbaI (which is compatible with AvrII) and SalI to form pFS16.
- Construction of pFS30
- The plasmid pFS30 was derived from pFS16 by adding theRalstonia eutropha PHA synthase (phaC) gene. The plasmid pAeT414 was digested with XmaI and StuI so that the R. eutropha promoter and the structural phaC gene were present on one fragment. pFS16 was cut with BamHI, treated with T4 DNA polymerase to create blunt ends, then digested with XmaI. The two DNA fragments thus obtained were ligated together to form pFS30.
- Construction of pMS59
- The aldH gene was removed from pMS33 by digestion with SpeI and BglII. Plasmid pTC42 (Skraly et al., 1998,Appl. Environ. Microbiol. 64:98-105), which contains the Klebsiella pneumoniae dhaT gene under the control of the trc promoter, was digested with NheI and BglII. SpeI and NheI form compatible sticky ends. The aldH-containing fragment of pMS33 and the large fragment of pTC42 were ligated together to form pMS59.
- Construction of pMS60
- The aldH-dhaT region was isolated from pMS59 by digestion with SpeI, followed by treatment with the Klenow fragment of DNA polymerase I and subsequent digestion with MfeI. This fragment had one blunt end and one sticky end compatible with EcoRI-generated sticky ends. pFS30 was digested with XmaI, followed by treatment with the Klenow fragment of DNA polymerase I and subsequent digestion with EcoRI. The large fragment of pFS30 and the aldH-dhaT-containing fragment of pMS59 were ligated together to form pMS60.
-
- Strain MBX1493 was transformed with four plasmids in separate procedures: pTrcN, pTC42, pMS33, and pMS59. These plasmids contain, under control of the trc promoter, the following genes, respectively: none, dhaT only, aldH only, both aldH and dhaT. Each of these strains was grown in 3 mL LB supplemented with 100 μg/mL ampicillin at 37° C. with shaking overnight. A volume of 1 mL of each of these cultures was used as an inoculum into 50 mL of a medium containing, per liter: 1 mmol MgSO4; 10 mg thiamine; 25.5 mmol Na2HPO4; 33.3 mmol K2HPO4; 27.2 mmol KH2PO4; 2.78 mg FeSO4.7H2O; 1.98 mg MnCl2.4H2O; 2.81 mg CoSO4.7H2O; 0.17 mg CuCl2.2H2O; 1.67 mg CaCl2.2H2O; 0.29 mg ZnSO4.7H2O; 10 g glucose; 5 g 4-hydroxybutyrate or 10 g 1,4-butanediol; 100 μg ampicillin; 25 μg chloramphenicol; and 0.01 mmol IPTG. These cultures were incubated at 30° C. with shaking at 250 rpm for 88 hours. The cells were removed from this medium by centrifugation (2000 g, 10 min.), and they were lyophilized and analyzed for PHA content and composition by GC. Table 1 shows the composition of the polymers made by these strains and the final optical densities (600 nm) of the cultures.
- As shown in Table 1, all strains produce a copolymer with a significant percentage of 4HB when fed 4HB. However, when fed 1,4-butanediol, only the pMS59-containing cells, that is, the cells expressing both aldH and dhaT, achieved a significant level of 4HB incorporation into the polymer. Thus the aldH-dhaT pathway was shown to enable the conversion of 1,4-butanediol to 4HB and not to interfere significantly with cell health or the subsequent incorporation of 4HB into a PHA.
TABLE 1 Conversion of 1,4-butanediol to 4HB PHA 4HB Substrate Plasmid OD (600 nm) % dcwa % of polymerb 4HB pTrcN 19.2 53.0 36.6 4HB pTC42 18.8 62.7 16.0 4HB pMS33 14.8 49.8 21.4 4HB pMS59 22.8 43.5 32.2 1,4-BD pTrcN 16.0 41.0 1.1 1,4-BD pTC42 10.4 38.7 0.7 1,4-BD pMS33 10.8 40.6 2.9 1,4-BD pMS59 10.4 34.6 25.3 -
- Each strain was grown in LB broth supplemented with 100 μg/mL ampicillin overnight at 37° C. with shaking at 250 rpm. The cells were then removed from the medium by centrifugation (2000 g, 10 min.) and resuspended in 50 mL of a medium containing, per liter: 2.5 g LB powder; 50 mmol potassium phosphate, pH 7.0; 5 g glucose; 0 or 10 g 1,3-propanediol; 100 μg ampicillin; and 0.1 mmol IPTG. These incubations were at 30° C. with shaking at 250 rpm for 25 hours. The cells were removed from the medium by centrifugation as described above, washed with water, centrifuged again, lyophilized, and analyzed for PHA content and composition by GC. The standard used to test for the presence of 3-hydroxypropionate units in the polymer was beta-propiolactone (Aldrich Chemical Co.; Milwaukee, Wis.).
- In the flasks without added 1,3-propanediol, no PHP formation was detected; strains LS5218/pFS30 and LS5218/pMS60 reached optical densities (600 nm) of 4.6 and 8.2, respectively. In the flasks with added 1,3-propanediol, strain LS5218/pFS30 reached an optical density (600 nm) of 5.2 and did not accumulate poly-3HP to a detectable level, while strain LS5218/pMS60 reached an optical density (600 nm) of 6.6 and had accumulated poly-3HP to 5.0% of the dry cell weight. Thus expression of the aldH and dhaT genes is sufficient to increase the ability ofE. coli LS5218 to synthesize poly-3HP from 1,3-propanediol.
- Strain MBX1493 was transformed with four plasmids in separate procedures: pTrcN, pTC42, pMS33, and pMS59. Each of these strains was grown in 100 mL LB supplemented with 100 μg/mL ampicillin at 37° C. with shaking overnight. The cells were decanted from each flask, and the residual liquid was retained. To each flask was then added 80 mL of a medium containing, per liter: 6.25 g LB powder; 1 mmol MgSO4; 10 mg thiamine; 25.5 mmol Na2HPO4; 33.3 mmol K2HPO4; 27.2 mmol KH2PO4; 2.78 mg FeSO4.7H2O; 1.98 mg MnCl2.4H2O; 2.81 mg CoSO4.7H2O; 0.17 mg CuCl2.2H2O; 1.67 mg CaCl2.2H2O; 0.29 mg ZnSO4.7H2O; 10 g glucose; 100 μg ampicillin; 25 μg chloramphenicol; and 0.01 mmol IPTG. These cultures were incubated at 37° C. with shaking at 250 rpm for 7 hours. To each flask was then added 20 mL of the same medium given above, except that in this medium LB was increased to 12.5 g/L, glucose was increased to 100 g/L, IPTG was increased to 0.25 mM, and 1,3-propanediol was added at 50 g/L. Thus the final concentrations added at this stage were 2.5 g/L LB, 20 g/L glucose, 10 g/L 1,3-propanediol, and 0.05 mM IPTG. These flasks were incubated at 30° C. for 24 hours with shaking at 250 rpm. The cells were then removed from this medium by centrifugation (2000 g, 10 min.), and they were lyophilized and analyzed for PHA content and composition by GC. Table 2 shows the composition of the polymers made by these strains and the final optical densities (600 nm) of the cultures.
- In the absence of 1,3-propanediol, each strain synthesized only PHB. When fed 1,3-propanediol, only the pMS59-containing cells, that is, the cells expressing both aldH and dhaT, achieved a significant level of 3HP incorporation into the polymer. The cells containing pMS33, or aldH alone, do accomplish 3HP incorporation, but to only a small extent. Thus the aldH-dhaT pathway was shown to enable the conversion of 1,3-propanediol to 3HP. The cells containing the dhaT gene (pTC42 and pMS59) made less total polymer when 1,3-propanediol was present, and this is most likely due to the toxicity of 3-hydroxypropionaldehyde. Increasing the ratio of aldH to dhaT expression and/or reducing 1,3-propanediol concentration should subdue this phenomenon.
TABLE 2 Incorporation of 3HP into PHA by MBX1493 Containing Various Plasmids 1,3-Propanediol PHA 3HP g/L Plasmid % dcwa % of polymerb 0 pTrcN 35.2 0.0 0 pTC42 46.0 0.0 0 pMS33 31.2 0.0 0 pMS59 37.7 0.0 10 pTrcN 36.6 0.0 10 pTC42 23.9 0.0 10 pMS33 39.6 0.3 10 pMS59 20.0 3.8 - Strain MBX1668, which has the aldH and dhaT genes integrated into its chromosome as an operon along with the tetracycline resistance marker from Tn10, was transformed with either of two plasmids: pFS73 or pMS92. The plasmid pFS73 is the same as pFS30 described in previous examples except that the ampicillin resistance marker has been replaced with the kanamycin resistance marker from pACYC177 (GenBank Accession No. X06402). The plasmid pMS92 is derived from pFS73, the orfZ gene having been replaced with the alkK gene fromPseudomonas oleovorans (van Beilen et al., 1992, Mol. Microbiol. 6:3121-36). Each of these strains was grown in 3 mL LB supplemented with 50 μg/mL kanamycin and 10 μg/mL tetracycline at 37° C. with shaking overnight. One milliliter of each culture was added as an inoculum to a 200-mL square bottle. Each bottle held 50 mL of a medium containing, per liter: 0.1 g casamino acids; 5 mmol MgSO4; 10 mg thiamine; 25.5 mmol Na2HPO4; 33.3 mmol K2HPO4; 27.2 mmol KH2PO4; 2.78 mg FeSO4.7H2O; 1.98 mg MnCl2.4H2O; 2.81 mg CoSO4.7H2O; 0.17 mg CuCl2.2H2O; 1.67 mg CaCl2.2H2O; 0.29 mg ZnSO4.7H2O; 10 g glucose; 10 g 1,4-butanediol; 50 μg kanamycin; and 10 μg tetracycline. These cultures were incubated at 30° C. with shaking at 250 rpm for 48 hours. The cells were then removed from this medium by centrifugation (2000 g, 10 min.), and they were lyophilized and analyzed for PHA content and composition by GC. Strain MBX1668 harboring pFS73 contained 5.8% poly(4HB) by dry weight, while MBX1668 harboring pMS92 contained 27.7% poly(4HB) by dry weight. Thus the alkK gene is an acceptable, and in this case better, substitute for the orfZ gene in the synthesis of PHAs from diols.
- Modifications and variations of the methods and materials described herein will be obvious to those skilled in the art and are intended to come within the scope of the following claims.
-
1 8 1 44 DNA Artificial sequence 4hbD 5′ EcoRI primer 1 ctctgaattc aaggaggaaa aaatatgaag ttattaaaat tggc 44 2 34 DNA Artificial sequence 4hbD 3′ SacI primer 2 tttctctgag ctcgggatat ttaatgattg tagg 34 3 47 DNA E. coli misc_feature aldH 5′ Acc65I primer 3 ggtggtacct taagaggagg tttttatgaa ttttcatcac ctggctt 47 4 32 DNA E. coli misc_feature aldH 3′ NotI 4 ggtgcggccg ctcaggcctc caggcttatc ca 32 5 47 DNA Ralstonia eutropha misc_feature gbd 5′ EcoRI primer 5 cctgaattca ggaggttttt atggcgttta tctactatct gacccac 47 6 32 DNA Ralstonia eutropha misc_feature gbd 3′ SacI primer 6 cctgagctcc tacctgcaag tgctcgccgc tc 32 7 49 DNA Clostridium kluyveri misc_feature orfZ 5′ AvrII primer 7 tcccctagga ttcaggaggt ttttatggag tgggaagaga tatataaag 49 8 38 DNA Clostridium kluyveri orfZ misc_feature orfZ 3′ SalI primer 8 ccttaagtcg acaaattcta aaatctcttt ttaaattc 38
Claims (21)
1. A method for producing polyhydroxyalkanoates comprising
providing genetically engineered organisms which express enzymes selected from the group consisting of diol oxidoreductase, aldehyde dehydrogenase, acyl-CoA transferase, acyl-CoA synthetase, β-ketothiolase, acetoacetyl-CoA reductase, and PHA synthase,
providing diols which can be converted into hydroxyalkanoate monomers by enzymes expressed by the organisms, and
culturing the organisms under conditions wherein the hydroxyalkanoate monomers are polymerized to form polyhydroxyalkanoates.
2. The method of claim 1 wherein the diol is 1,6-hexanediol and the hydroxyalkanoate monomer is 6-hydroxyhexanoate.
3. The method of claim 1 wherein the diol is 1,5-pentanediol and the hydroxyalkanoate monomer is 5-hydroxyvalerate.
4. The method of claim 1 wherein the diol is 1,4-butanediol and the hydroxyalkanoate is 4-hydroxybutyrate.
5. The method of claim 1 wherein the diol is 1,3-propanediol and the hydroxyalkanoate monomer is 3-hydroxypropionate.
6. The method of claim 1 wherein the diol is 1,2-ethanediol and the hydroxyalkanoate is 2-hydroxyethanoate.
7. The method of claim 1 wherein the diol is 1,2-propanediol and the hydroxyalkanoate is 2-hydroxypropionate.
8. A genetically engineered organism for use in the method of claim 1 comprising an organism which expresses the aldH and dhaT genes.
9. The organism of claim 8 wherein the organism is selected from the group consisting of Escherichia coli, Ralstonia eutropha, Klebsiella spp., Alcaligenes latus, Azotobacter spp., and Comamonas spp.
10. A system for making polyhydroxyalkanoates comprising an organism genetically engineered to express enzymes selected from the group consisting of a diol oxidoreductase, aldehyde dehydrogenase, acyl-CoA transferase, acyl-CoA synthetase, β-ketothiolase, acetoacetyl-CoA reductase, and PHA synthase,
wherein the organism can convert diols into hydroxyalkanoate monomers which are polymerized to form polyhydroxyalkanoates.
11. A composition comprising a polyhydroxyalkanoate copolymer which includes
2-hydroxypropionate or 2-hydroxyethanoate or both, and
at least one comonomer selected from the group consisting of 3-hydroxybutyrate, 4-hydroxybutyrate, 3-hydroxypropionate, 2-hydroxybutyrate, 4-hydroxyvalerate, 5-hydroxyvalerate, 6-hydroxyhexanoate, and 3-hydroxyhexanoate, having a weight-average molecular weight (Mw) of at least 300,000.
12. The composition of example 11 where the comonomer is 3-hydroxybutyrate.
13. The composition of example 11 where the comonomer is 4-hydroxybutyrate.
14. The composition of example 11 where the comonomer is 3-hydroxypropionate.
15. The composition of example 11 where the comonomer is 2-hydroxybutyrate.
16. The composition of example 11 where the comonomer is 4-hydroxyvalerate.
17. The composition of example 11 where the comonomer is 5-hydroxyvalerate.
18. The composition of example 11 where the comonomer is 6-hydroxyhexanoate.
19. The composition of example 11 where the comonomer is 3-hydroxyhexanoate.
20. A method for improving a biological system for making polyhydroxyalkanoates with an organism genetically engineered to express enzymes selected from the group consisting of a diol oxidoreductase, aldehyde dehydrogenase, acyl-CoA transferase, acyl-CoA synthetase, β-ketothiolase, acetoacetyl-CoA reductase, and PHA synthase, wherein the organism can convert diols into hydroxyalkanoate monomers which are polymerized to form polyhydroxyalkanoates, the method comprising selecting for mutants with increased enzyme activities by
i) introducing mutations into a specific host, and
ii) screening pools of the mutants generated for increased ability to synthesize PHA from a selected diol or diols.
21. A DNA fragment encoding a diol oxidoreductase and an aldehyde dehydrogenase, wherein the expressed enzymes can produce hydroxyalkanoate monomer selected from the group consisting of 3-hydroxybutyrate, 4-hydroxybutyrate, 3-hydroxypropionate, 2-hydroxybutyrate, 4-hydroxyvalerate, 5-hydroxyvalerate, 6-hydroxyhexanoate, 3-hydroxyhexanoate, 2-hydroxypropionate, and 2-hydroxyethanoate from diol.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/909,574 US20020164729A1 (en) | 2000-07-21 | 2001-07-20 | Production of polyhydroxyalkanoates from polyols |
US12/539,079 US8741624B2 (en) | 2000-07-21 | 2009-08-11 | Production of polyhydroxyalkanoates from polyols |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21999500P | 2000-07-21 | 2000-07-21 | |
US09/909,574 US20020164729A1 (en) | 2000-07-21 | 2001-07-20 | Production of polyhydroxyalkanoates from polyols |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/539,079 Continuation US8741624B2 (en) | 2000-07-21 | 2009-08-11 | Production of polyhydroxyalkanoates from polyols |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020164729A1 true US20020164729A1 (en) | 2002-11-07 |
Family
ID=22821601
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/909,574 Abandoned US20020164729A1 (en) | 2000-07-21 | 2001-07-20 | Production of polyhydroxyalkanoates from polyols |
US12/539,079 Expired - Fee Related US8741624B2 (en) | 2000-07-21 | 2009-08-11 | Production of polyhydroxyalkanoates from polyols |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/539,079 Expired - Fee Related US8741624B2 (en) | 2000-07-21 | 2009-08-11 | Production of polyhydroxyalkanoates from polyols |
Country Status (8)
Country | Link |
---|---|
US (2) | US20020164729A1 (en) |
EP (1) | EP1305439B1 (en) |
JP (1) | JP4860094B2 (en) |
KR (1) | KR20040014389A (en) |
AT (1) | ATE329048T1 (en) |
AU (2) | AU2001275996B2 (en) |
DE (1) | DE60120415T2 (en) |
WO (1) | WO2002008428A2 (en) |
Cited By (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030211131A1 (en) * | 2002-05-10 | 2003-11-13 | Metabolix, Inc. | Bioabsorbable polymer containing 2-hydroxyacid monomers |
DE102004030385A1 (en) * | 2004-06-23 | 2006-01-19 | Sächsisches Institut für Angewandte Biotechnologie e.V. (SIAB) | Biosynthesis of poly(D-3-hydroxybutyric acid-co-4-hydroxybutyric acid) (P(3HB/4HB)) of definite 4HB content involves culturing of Delftia acidovorans (P4a) |
US20060124545A1 (en) * | 2003-05-06 | 2006-06-15 | Tate & Lyle Ingredients Americas, Inc. | Process for producing 1,3-propanediol |
US7209916B1 (en) | 2002-06-26 | 2007-04-24 | Microsoft Corporation | Expression and flexibility framework for providing notification(s) |
US20080032370A1 (en) * | 2004-04-27 | 2008-02-07 | Mitsui Chemicals, Inc. | Process for Producng Hydroxycarboxylic Acid |
WO2008062996A1 (en) * | 2006-11-21 | 2008-05-29 | Lg Chem, Ltd. | Copolymer containing 3-hydroxyalkanoate unit and lactate unit, and its manufacturing method |
US20090047719A1 (en) * | 2007-08-10 | 2009-02-19 | Burgard Anthony P | Methods and organisms for the growth-coupled production of 1,4-butanediol |
US7678123B2 (en) | 2003-07-14 | 2010-03-16 | Nmt Medical, Inc. | Tubular patent foramen ovale (PFO) closure device with catch system |
US7766820B2 (en) | 2002-10-25 | 2010-08-03 | Nmt Medical, Inc. | Expandable sheath tubing |
US20100210017A1 (en) * | 2007-01-12 | 2010-08-19 | Gill Ryan T | Compositions and methods for enhancing tolerance for the production of organic chemicals produced by microorganisms |
US7842053B2 (en) | 2004-05-06 | 2010-11-30 | Nmt Medical, Inc. | Double coil occluder |
US7858350B2 (en) | 2008-09-10 | 2010-12-28 | Genomatica, Inc. | Microorganisms for the production of 1,4-butanediol |
WO2010151798A2 (en) | 2009-06-26 | 2010-12-29 | Metabolix, Inc. | Pha compositions comprising pbs and pbsa and methods for their production |
US7867250B2 (en) | 2001-12-19 | 2011-01-11 | Nmt Medical, Inc. | Septal occluder and associated methods |
US7871419B2 (en) | 2004-03-03 | 2011-01-18 | Nmt Medical, Inc. | Delivery/recovery system for septal occluder |
US20110129899A1 (en) * | 2009-10-13 | 2011-06-02 | Robert Haselbeck | Microorganisms for the production of 1,4-butanediol, 4-hydroxybutanal, 4-hydroxybutyryl-coa, putrescine and related compounds, and methods related thereto |
WO2011068952A1 (en) | 2009-12-02 | 2011-06-09 | Entrigue Surgical, Inc. | Devices for tongue stabilization |
US7963952B2 (en) | 2003-08-19 | 2011-06-21 | Wright Jr John A | Expandable sheath tubing |
US7967840B2 (en) | 2001-12-19 | 2011-06-28 | Nmt Medical, Inc. | PFO closure device with flexible thrombogenic joint and improved dislodgement resistance |
US20110201090A1 (en) * | 2010-02-12 | 2011-08-18 | Gevo, Inc. | Yeast microorganisms with reduced by-product accumulation for improved production of fuels, chemicals, and amino acids |
US8048624B1 (en) | 2007-12-04 | 2011-11-01 | Opx Biotechnologies, Inc. | Compositions and methods for 3-hydroxypropionate bio-production from biomass |
US8048661B2 (en) | 2010-02-23 | 2011-11-01 | Genomatica, Inc. | Microbial organisms comprising exogenous nucleic acids encoding reductive TCA pathway enzymes |
US8067214B2 (en) | 2007-03-16 | 2011-11-29 | Genomatica, Inc. | Compositions and methods for the biosynthesis of 1,4-butanediol and its precursors |
US8129169B2 (en) | 2009-06-04 | 2012-03-06 | Genomatica, Inc. | Microorganisms for the production of 1,4-butanediol and related methods |
US8257389B2 (en) | 2004-05-07 | 2012-09-04 | W.L. Gore & Associates, Inc. | Catching mechanisms for tubular septal occluder |
US8277480B2 (en) | 2005-03-18 | 2012-10-02 | W.L. Gore & Associates, Inc. | Catch member for PFO occluder |
WO2012142100A1 (en) | 2011-04-13 | 2012-10-18 | Metabolix, Inc. | Biodegradable coextruded multilayer films |
WO2012149407A1 (en) | 2011-04-29 | 2012-11-01 | Metabolix, Inc. | Process for latex production by melt emulsification |
US8308760B2 (en) | 2004-05-06 | 2012-11-13 | W.L. Gore & Associates, Inc. | Delivery systems and methods for PFO closure device with two anchors |
US8361110B2 (en) | 2004-04-26 | 2013-01-29 | W.L. Gore & Associates, Inc. | Heart-shaped PFO closure device |
US8445244B2 (en) | 2010-02-23 | 2013-05-21 | Genomatica, Inc. | Methods for increasing product yields |
US8480706B2 (en) | 2003-07-14 | 2013-07-09 | W.L. Gore & Associates, Inc. | Tubular patent foramen ovale (PFO) closure device with catch system |
US8530210B2 (en) | 2009-11-25 | 2013-09-10 | Genomatica, Inc. | Microorganisms and methods for the coproduction 1,4-butanediol and gamma-butyrolactone |
US8551135B2 (en) | 2006-03-31 | 2013-10-08 | W.L. Gore & Associates, Inc. | Screw catch mechanism for PFO occluder and method of use |
US8597918B2 (en) | 2009-06-04 | 2013-12-03 | Genomatica, Inc. | Process of separating components of a fermentation broth |
WO2013184822A1 (en) | 2012-06-05 | 2013-12-12 | Metabolix, Inc. | Biobased rubber modified biodegradable polymer blends |
WO2014028943A1 (en) | 2012-08-17 | 2014-02-20 | Metabolix, Inc. | Biobased rubber modifiers for polymer blends |
US8753362B2 (en) | 2003-12-09 | 2014-06-17 | W.L. Gore & Associates, Inc. | Double spiral patent foramen ovale closure clamp |
US8764848B2 (en) | 2004-09-24 | 2014-07-01 | W.L. Gore & Associates, Inc. | Occluder device double securement system for delivery/recovery of such occluder device |
US8784448B2 (en) | 2002-06-05 | 2014-07-22 | W.L. Gore & Associates, Inc. | Patent foramen ovale (PFO) closure device with radial and circumferential support |
US8809027B1 (en) | 2009-09-27 | 2014-08-19 | Opx Biotechnologies, Inc. | Genetically modified organisms for increased microbial production of 3-hydroxypropionic acid involving an oxaloacetate alpha-decarboxylase |
US20140234944A1 (en) * | 2011-04-29 | 2014-08-21 | Metabolix, Inc. | Green Process for Producing Polyhydroxyalkanoates and Chemicals Using a Renewable Feedstock |
US8814947B2 (en) | 2006-03-31 | 2014-08-26 | W.L. Gore & Associates, Inc. | Deformable flap catch mechanism for occluder device |
US8828049B2 (en) | 2004-04-09 | 2014-09-09 | W.L. Gore & Associates, Inc. | Split ends closure device and methods of use |
US8870913B2 (en) | 2006-03-31 | 2014-10-28 | W.L. Gore & Associates, Inc. | Catch system with locking cap for patent foramen ovale (PFO) occluder |
US8883464B2 (en) | 2009-09-27 | 2014-11-11 | Opx Biotechnologies, Inc. | Methods for producing 3-hydroxypropionic acid and other products |
WO2014194220A1 (en) | 2013-05-30 | 2014-12-04 | Metabolix, Inc. | Recyclate blends |
US9005242B2 (en) | 2007-04-05 | 2015-04-14 | W.L. Gore & Associates, Inc. | Septal closure device with centering mechanism |
US9017373B2 (en) | 2002-12-09 | 2015-04-28 | W.L. Gore & Associates, Inc. | Septal closure devices |
US9078634B2 (en) | 2011-01-27 | 2015-07-14 | Cryosa, Llc | Apparatus and methods for treatment of obstructive sleep apnea utilizing cryolysis of adipose tissues |
US9084603B2 (en) | 2005-12-22 | 2015-07-21 | W.L. Gore & Associates, Inc. | Catch members for occluder devices |
US9138562B2 (en) | 2007-04-18 | 2015-09-22 | W.L. Gore & Associates, Inc. | Flexible catheter system |
US9241695B2 (en) | 2002-03-25 | 2016-01-26 | W.L. Gore & Associates, Inc. | Patent foramen ovale (PFO) closure clips |
US9474517B2 (en) | 2008-03-07 | 2016-10-25 | W. L. Gore & Associates, Inc. | Heart occlusion devices |
US9512057B2 (en) | 2013-03-15 | 2016-12-06 | Cargill, Incorporated | 3-hydroxypropionic acid compositions |
WO2017087658A1 (en) | 2015-11-17 | 2017-05-26 | Cj Research Center, Llc | Polymer blends with controllable biodegradation rates |
US9677045B2 (en) | 2012-06-04 | 2017-06-13 | Genomatica, Inc. | Microorganisms and methods for production of 4-hydroxybutyrate, 1,4-butanediol and related compounds |
US9770232B2 (en) | 2011-08-12 | 2017-09-26 | W. L. Gore & Associates, Inc. | Heart occlusion devices |
US9808230B2 (en) | 2014-06-06 | 2017-11-07 | W. L. Gore & Associates, Inc. | Sealing device and delivery system |
US9861346B2 (en) | 2003-07-14 | 2018-01-09 | W. L. Gore & Associates, Inc. | Patent foramen ovale (PFO) closure device with linearly elongating petals |
US10047383B2 (en) | 2013-03-15 | 2018-08-14 | Cargill, Incorporated | Bioproduction of chemicals |
US10337038B2 (en) | 2013-07-19 | 2019-07-02 | Cargill, Incorporated | Microorganisms and methods for the production of fatty acids and fatty acid derived products |
US10465213B2 (en) | 2012-08-10 | 2019-11-05 | Cargill, Incorporated | Microorganisms and methods for the production of fatty acids and fatty acid derived products |
US10494654B2 (en) | 2014-09-02 | 2019-12-03 | Cargill, Incorporated | Production of fatty acids esters |
US10792025B2 (en) | 2009-06-22 | 2020-10-06 | W. L. Gore & Associates, Inc. | Sealing device and delivery system |
US10806437B2 (en) | 2009-06-22 | 2020-10-20 | W. L. Gore & Associates, Inc. | Sealing device and delivery system |
US10828019B2 (en) | 2013-01-18 | 2020-11-10 | W.L. Gore & Associates, Inc. | Sealing device and delivery system |
US11286510B2 (en) | 2018-03-15 | 2022-03-29 | Lg Chem, Ltd. | Poly(3-hydroxypropionate-b-lactate) block copolymer using microorganisms |
US11345938B2 (en) | 2017-02-02 | 2022-05-31 | Cargill, Incorporated | Genetically modified cells that produce C6-C10 fatty acid derivatives |
US11408013B2 (en) | 2013-07-19 | 2022-08-09 | Cargill, Incorporated | Microorganisms and methods for the production of fatty acids and fatty acid derived products |
US11535873B2 (en) | 2017-09-07 | 2022-12-27 | The Governing Council Of The University Of Toronto | Production of glycolate from ethylene glycol and related microbial engineering |
US11534335B2 (en) | 2014-10-01 | 2022-12-27 | Cryosa, Inc. | Apparatus and methods for treatment of obstructive sleep apnea utilizing cryolysis of adipose tissues |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7165624B1 (en) * | 1998-05-15 | 2007-01-23 | Grinnell Corporation | Early suppression fast response fire protection sprinkler |
WO2004024876A2 (en) | 2002-09-12 | 2004-03-25 | Metabolix, Inc. | Polyhydroxyalkanoate production by coenzyme a-dependent aldehyde dehydrogenase pathways |
US7476521B2 (en) | 2003-01-22 | 2009-01-13 | Showa Denko K.K. | Method for acyltransferase reaction using acyl coenzyme A |
BRPI0718974B1 (en) * | 2006-11-21 | 2020-12-15 | Lg Chem, Ltd. | METHOD FOR PREPARING A COPOLYMER |
KR100957773B1 (en) | 2006-11-23 | 2010-05-12 | 주식회사 엘지화학 | Novel Copolymer of [Poly3-hydroxypropionate-co-lactate] and Method for Preparing the Same |
US20110009593A1 (en) * | 2007-10-03 | 2011-01-13 | President And Fellows Of Harvard College | Polymeric Bioplastics |
US20110190513A1 (en) * | 2008-07-08 | 2011-08-04 | Lynch Michael D | Methods, compositions and systems for biosynthetic bio-production of 1,4-butanediol |
EP2310518A1 (en) * | 2008-07-11 | 2011-04-20 | Metabolic Explorer | Method for polymerising glycolic acid with microorganisms |
TW201042103A (en) | 2008-12-23 | 2010-12-01 | Metabolix Inc | Production of non-woven materials from polyhydroxyalkanoate |
ES2503552T3 (en) | 2009-04-06 | 2014-10-07 | Metabolix, Inc. | Method of improving film processing and injection molding of polyhydroxyalkanoate polymers |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6576450B2 (en) * | 1998-08-04 | 2003-06-10 | Metabolix, Inc. | Polyhydroxyalkanoate production from polyols |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1642111A1 (en) * | 1965-04-20 | 1971-12-30 | Ethicon Inc | Surgical sutures and process for their manufacture |
US3579549A (en) * | 1967-09-29 | 1971-05-18 | Nat Starch Chem Corp | Acyl derivatives of the condensation polymers of alpha-hydroxy-propionic acid with beta-hydroxybutyric acid and/or beta-hydroxypropionic acid |
CS277545B6 (en) * | 1991-05-15 | 1993-03-17 | Farmaceuticka Fakulta Uk | Process for preparing hydroxy carboxylic acid oligoesters |
JPH0616790A (en) * | 1991-08-13 | 1994-01-25 | Toyobo Co Ltd | Aliphatic polyester and its production |
JP3408557B2 (en) * | 1992-06-11 | 2003-05-19 | 三井化学株式会社 | Vehicle mounted lamp and manufacturing method thereof |
US5294469A (en) * | 1992-06-17 | 1994-03-15 | Mitsui Toatsu Chemicals, Incorporated | Industrial woven fabric and composite sheet comprising same |
JPH06304253A (en) * | 1993-04-23 | 1994-11-01 | Mitsui Toatsu Chem Inc | Injection cylinder |
JPH08226016A (en) * | 1995-02-20 | 1996-09-03 | Mitsubishi Rayon Co Ltd | Polylactic acid fiber and its production |
DE69733490T2 (en) | 1997-03-03 | 2006-03-16 | Metabolix, Inc., Cambridge | METHOD FOR POLYESTER BIOSYNTHESIS |
US6156852A (en) | 1997-04-21 | 2000-12-05 | Monsanto Company | Hydroxy-terminated polyhydroxyalkanoates |
ATE323152T1 (en) | 1997-09-19 | 2006-04-15 | Metabolix Inc | BIOLOGICAL SYSTEMS FOR THE PRODUCTION OF POLYHYDROXYALKANOATE POLYMERS THAT CONTAIN 4-HYDROXY ACID |
ATE483023T1 (en) * | 1998-05-22 | 2010-10-15 | Metabolix Inc | POLYHYDROXYALKANOOATBIOPOLYMERS |
WO2000011188A1 (en) * | 1998-08-18 | 2000-03-02 | Metabolix, Inc. | Transgenic microbial polyhydroxyalkanoate producers |
-
2001
- 2001-07-20 EP EP01953560A patent/EP1305439B1/en not_active Expired - Lifetime
- 2001-07-20 DE DE60120415T patent/DE60120415T2/en not_active Expired - Lifetime
- 2001-07-20 AU AU2001275996A patent/AU2001275996B2/en not_active Expired
- 2001-07-20 AU AU7599601A patent/AU7599601A/en active Pending
- 2001-07-20 AT AT01953560T patent/ATE329048T1/en not_active IP Right Cessation
- 2001-07-20 KR KR10-2003-7000908A patent/KR20040014389A/en active Search and Examination
- 2001-07-20 WO PCT/US2001/022834 patent/WO2002008428A2/en active IP Right Grant
- 2001-07-20 US US09/909,574 patent/US20020164729A1/en not_active Abandoned
- 2001-07-20 JP JP2002513911A patent/JP4860094B2/en not_active Expired - Lifetime
-
2009
- 2009-08-11 US US12/539,079 patent/US8741624B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6576450B2 (en) * | 1998-08-04 | 2003-06-10 | Metabolix, Inc. | Polyhydroxyalkanoate production from polyols |
Cited By (142)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7967840B2 (en) | 2001-12-19 | 2011-06-28 | Nmt Medical, Inc. | PFO closure device with flexible thrombogenic joint and improved dislodgement resistance |
US7867250B2 (en) | 2001-12-19 | 2011-01-11 | Nmt Medical, Inc. | Septal occluder and associated methods |
US8758403B2 (en) | 2001-12-19 | 2014-06-24 | W.L. Gore & Associates, Inc. | PFO closure device with flexible thrombogenic joint and improved dislodgement resistance |
US9241695B2 (en) | 2002-03-25 | 2016-01-26 | W.L. Gore & Associates, Inc. | Patent foramen ovale (PFO) closure clips |
US8703449B2 (en) | 2002-05-10 | 2014-04-22 | Metabolix, Inc. | Bioabsorbable polymer containing 2-hydroxyacid monomers |
US20030211131A1 (en) * | 2002-05-10 | 2003-11-13 | Metabolix, Inc. | Bioabsorbable polymer containing 2-hydroxyacid monomers |
US8039237B2 (en) * | 2002-05-10 | 2011-10-18 | Metabolix, Inc. | Bioabsorbable polymer containing 2-hydroxyacid monomers |
US9028527B2 (en) | 2002-06-05 | 2015-05-12 | W.L. Gore & Associates, Inc. | Patent foramen ovale (PFO) closure device with radial and circumferential support |
US8784448B2 (en) | 2002-06-05 | 2014-07-22 | W.L. Gore & Associates, Inc. | Patent foramen ovale (PFO) closure device with radial and circumferential support |
US7209916B1 (en) | 2002-06-26 | 2007-04-24 | Microsoft Corporation | Expression and flexibility framework for providing notification(s) |
US7766820B2 (en) | 2002-10-25 | 2010-08-03 | Nmt Medical, Inc. | Expandable sheath tubing |
US9017373B2 (en) | 2002-12-09 | 2015-04-28 | W.L. Gore & Associates, Inc. | Septal closure devices |
US20060124545A1 (en) * | 2003-05-06 | 2006-06-15 | Tate & Lyle Ingredients Americas, Inc. | Process for producing 1,3-propanediol |
US7572376B2 (en) | 2003-05-06 | 2009-08-11 | Tate & Lyle Ingredients Americas, Inc. | Process for producing 1,3-propanediol |
US9326759B2 (en) | 2003-07-14 | 2016-05-03 | W.L. Gore & Associates, Inc. | Tubular patent foramen ovale (PFO) closure device with catch system |
US8480706B2 (en) | 2003-07-14 | 2013-07-09 | W.L. Gore & Associates, Inc. | Tubular patent foramen ovale (PFO) closure device with catch system |
US11375988B2 (en) | 2003-07-14 | 2022-07-05 | W. L. Gore & Associates, Inc. | Patent foramen ovale (PFO) closure device with linearly elongating petals |
US9149263B2 (en) | 2003-07-14 | 2015-10-06 | W. L. Gore & Associates, Inc. | Tubular patent foramen ovale (PFO) closure device with catch system |
US9861346B2 (en) | 2003-07-14 | 2018-01-09 | W. L. Gore & Associates, Inc. | Patent foramen ovale (PFO) closure device with linearly elongating petals |
US7678123B2 (en) | 2003-07-14 | 2010-03-16 | Nmt Medical, Inc. | Tubular patent foramen ovale (PFO) closure device with catch system |
US7963952B2 (en) | 2003-08-19 | 2011-06-21 | Wright Jr John A | Expandable sheath tubing |
US8753362B2 (en) | 2003-12-09 | 2014-06-17 | W.L. Gore & Associates, Inc. | Double spiral patent foramen ovale closure clamp |
US7871419B2 (en) | 2004-03-03 | 2011-01-18 | Nmt Medical, Inc. | Delivery/recovery system for septal occluder |
US8945158B2 (en) | 2004-03-03 | 2015-02-03 | W.L. Gore & Associates, Inc. | Delivery/recovery system for septal occluder |
US8568431B2 (en) | 2004-03-03 | 2013-10-29 | W.L. Gore & Associates, Inc. | Delivery/recovery system for septal occluder |
US8828049B2 (en) | 2004-04-09 | 2014-09-09 | W.L. Gore & Associates, Inc. | Split ends closure device and methods of use |
US8361110B2 (en) | 2004-04-26 | 2013-01-29 | W.L. Gore & Associates, Inc. | Heart-shaped PFO closure device |
CN1954078B (en) * | 2004-04-27 | 2013-01-16 | 三井化学株式会社 | Process for producing hydroxycarboxylic acid |
US8728780B2 (en) | 2004-04-27 | 2014-05-20 | Mitsui Chemicals, Inc. | Process for producing hydroxycarboxylic acid |
US20080032370A1 (en) * | 2004-04-27 | 2008-02-07 | Mitsui Chemicals, Inc. | Process for Producng Hydroxycarboxylic Acid |
US8308760B2 (en) | 2004-05-06 | 2012-11-13 | W.L. Gore & Associates, Inc. | Delivery systems and methods for PFO closure device with two anchors |
US7842053B2 (en) | 2004-05-06 | 2010-11-30 | Nmt Medical, Inc. | Double coil occluder |
US8568447B2 (en) | 2004-05-06 | 2013-10-29 | W.L. Gore & Associates, Inc. | Delivery systems and methods for PFO closure device with two anchors |
US8480709B2 (en) | 2004-05-07 | 2013-07-09 | W.L. Gore & Associates, Inc. | Catching mechanisms for tubular septal occluder |
US9545247B2 (en) | 2004-05-07 | 2017-01-17 | W.L. Gore & Associates, Inc. | Catching mechanisms for tubular septal occluder |
US8257389B2 (en) | 2004-05-07 | 2012-09-04 | W.L. Gore & Associates, Inc. | Catching mechanisms for tubular septal occluder |
DE102004030385A1 (en) * | 2004-06-23 | 2006-01-19 | Sächsisches Institut für Angewandte Biotechnologie e.V. (SIAB) | Biosynthesis of poly(D-3-hydroxybutyric acid-co-4-hydroxybutyric acid) (P(3HB/4HB)) of definite 4HB content involves culturing of Delftia acidovorans (P4a) |
DE102004030385B4 (en) * | 2004-06-23 | 2008-02-07 | Sächsisches Institut für Angewandte Biotechnologie e.V. (SIAB) | Process for the preparation of poly (3-hydroxybutyric acid-co-4-hydroxybutyric acid) (P3HB / 4HB) of defined molar composition with Delftia acidovorans P4A |
US8764848B2 (en) | 2004-09-24 | 2014-07-01 | W.L. Gore & Associates, Inc. | Occluder device double securement system for delivery/recovery of such occluder device |
US8277480B2 (en) | 2005-03-18 | 2012-10-02 | W.L. Gore & Associates, Inc. | Catch member for PFO occluder |
US8636765B2 (en) | 2005-03-18 | 2014-01-28 | W.L. Gore & Associates, Inc. | Catch member for PFO occluder |
US8430907B2 (en) | 2005-03-18 | 2013-04-30 | W.L. Gore & Associates, Inc. | Catch member for PFO occluder |
US9084603B2 (en) | 2005-12-22 | 2015-07-21 | W.L. Gore & Associates, Inc. | Catch members for occluder devices |
US8814947B2 (en) | 2006-03-31 | 2014-08-26 | W.L. Gore & Associates, Inc. | Deformable flap catch mechanism for occluder device |
US8551135B2 (en) | 2006-03-31 | 2013-10-08 | W.L. Gore & Associates, Inc. | Screw catch mechanism for PFO occluder and method of use |
US8870913B2 (en) | 2006-03-31 | 2014-10-28 | W.L. Gore & Associates, Inc. | Catch system with locking cap for patent foramen ovale (PFO) occluder |
WO2008062996A1 (en) * | 2006-11-21 | 2008-05-29 | Lg Chem, Ltd. | Copolymer containing 3-hydroxyalkanoate unit and lactate unit, and its manufacturing method |
US20100210017A1 (en) * | 2007-01-12 | 2010-08-19 | Gill Ryan T | Compositions and methods for enhancing tolerance for the production of organic chemicals produced by microorganisms |
US8969054B2 (en) | 2007-03-16 | 2015-03-03 | Genomatica, Inc. | Compositions and methods for the biosynthesis of 1,4-butanediol and its precursors |
US9487803B2 (en) | 2007-03-16 | 2016-11-08 | Genomatica, Inc. | Compositions and methods for the biosynthesis of 1,4-butanediol and its precursors |
US8067214B2 (en) | 2007-03-16 | 2011-11-29 | Genomatica, Inc. | Compositions and methods for the biosynthesis of 1,4-butanediol and its precursors |
US8889399B2 (en) | 2007-03-16 | 2014-11-18 | Genomatica, Inc. | Compositions and methods for the biosynthesis of 1,4-butanediol and its precursors |
US8357520B2 (en) | 2007-03-16 | 2013-01-22 | Genomatica, Inc. | Compositions and methods for the biosynthesis of 1,4-butanediol and its precursors |
US11371046B2 (en) | 2007-03-16 | 2022-06-28 | Genomatica, Inc. | Compositions and methods for the biosynthesis of 1,4-butanediol and its precursors |
US9949728B2 (en) | 2007-04-05 | 2018-04-24 | W.L. Gore & Associates, Inc. | Septal closure device with centering mechanism |
US12059140B2 (en) | 2007-04-05 | 2024-08-13 | W. L. Gore & Associates, Inc. | Septal closure device with centering mechanism |
US10485525B2 (en) | 2007-04-05 | 2019-11-26 | W.L. Gore & Associates, Inc. | Septal closure device with centering mechanism |
US9005242B2 (en) | 2007-04-05 | 2015-04-14 | W.L. Gore & Associates, Inc. | Septal closure device with centering mechanism |
US9138562B2 (en) | 2007-04-18 | 2015-09-22 | W.L. Gore & Associates, Inc. | Flexible catheter system |
US20090047719A1 (en) * | 2007-08-10 | 2009-02-19 | Burgard Anthony P | Methods and organisms for the growth-coupled production of 1,4-butanediol |
US8470582B2 (en) | 2007-08-10 | 2013-06-25 | Genomatica, Inc. | Methods and organisms for the growth-coupled production of 1,4-butanediol |
US7947483B2 (en) | 2007-08-10 | 2011-05-24 | Genomatica, Inc. | Methods and organisms for the growth-coupled production of 1,4-butanediol |
US8652816B2 (en) | 2007-12-04 | 2014-02-18 | Opx Biotechnologies, Inc. | Compositions and methods for 3-hydroxypropionate bio-production from biomass |
US8048624B1 (en) | 2007-12-04 | 2011-11-01 | Opx Biotechnologies, Inc. | Compositions and methods for 3-hydroxypropionate bio-production from biomass |
US10278705B2 (en) | 2008-03-07 | 2019-05-07 | W. L. Gore & Associates, Inc. | Heart occlusion devices |
US9474517B2 (en) | 2008-03-07 | 2016-10-25 | W. L. Gore & Associates, Inc. | Heart occlusion devices |
US8129156B2 (en) | 2008-09-10 | 2012-03-06 | Genomatica, Inc. | Microorganisms for the production of 1,4-butanediol |
US9175297B2 (en) | 2008-09-10 | 2015-11-03 | Genomatica, Inc. | Microorganisms for the production of 1,4-Butanediol |
US8178327B2 (en) | 2008-09-10 | 2012-05-15 | Genomatica, Inc. | Microorganisms for the production of 1,4-butanediol |
US7858350B2 (en) | 2008-09-10 | 2010-12-28 | Genomatica, Inc. | Microorganisms for the production of 1,4-butanediol |
US8129169B2 (en) | 2009-06-04 | 2012-03-06 | Genomatica, Inc. | Microorganisms for the production of 1,4-butanediol and related methods |
US9434964B2 (en) | 2009-06-04 | 2016-09-06 | Genomatica, Inc. | Microorganisms for the production of 1,4-butanediol and related methods |
US10273508B2 (en) | 2009-06-04 | 2019-04-30 | Genomatica, Inc. | Microorganisms for the production of 1,4-butanediol and related methods |
US8597918B2 (en) | 2009-06-04 | 2013-12-03 | Genomatica, Inc. | Process of separating components of a fermentation broth |
US11401534B2 (en) | 2009-06-04 | 2022-08-02 | Genomatica, Inc. | Microorganisms for the production of 1,4- butanediol and related methods |
US11564672B2 (en) | 2009-06-22 | 2023-01-31 | W. L. Gore & Associates, Inc. | Sealing device and delivery system |
US12082795B2 (en) | 2009-06-22 | 2024-09-10 | W. L. Gore & Associates, Inc. | Sealing device and delivery system |
US10806437B2 (en) | 2009-06-22 | 2020-10-20 | W. L. Gore & Associates, Inc. | Sealing device and delivery system |
US10792025B2 (en) | 2009-06-22 | 2020-10-06 | W. L. Gore & Associates, Inc. | Sealing device and delivery system |
US11589853B2 (en) | 2009-06-22 | 2023-02-28 | W. L. Gore & Associates, Inc. | Sealing device and delivery system |
US11596391B2 (en) | 2009-06-22 | 2023-03-07 | W. L. Gore & Associates, Inc. | Sealing device and delivery system |
WO2010151798A2 (en) | 2009-06-26 | 2010-12-29 | Metabolix, Inc. | Pha compositions comprising pbs and pbsa and methods for their production |
EP3360927A1 (en) | 2009-06-26 | 2018-08-15 | CJ CheilJedang Corporation | Pha compositions comprising pbs and pbsa and method for producing the compositions |
US9428778B2 (en) | 2009-09-27 | 2016-08-30 | Cargill, Incorporated | Method for producing 3-hydroxypropionic acid and other products |
US9388419B2 (en) | 2009-09-27 | 2016-07-12 | Cargill, Incorporated | Methods for producing 3-hydroxypropionic acid and other products |
US8809027B1 (en) | 2009-09-27 | 2014-08-19 | Opx Biotechnologies, Inc. | Genetically modified organisms for increased microbial production of 3-hydroxypropionic acid involving an oxaloacetate alpha-decarboxylase |
US10100342B2 (en) | 2009-09-27 | 2018-10-16 | Cargill, Incorporated | Method for producing 3-hydroxypropionic acid and other products |
US8883464B2 (en) | 2009-09-27 | 2014-11-11 | Opx Biotechnologies, Inc. | Methods for producing 3-hydroxypropionic acid and other products |
US8377666B2 (en) | 2009-10-13 | 2013-02-19 | Genomatica, Inc. | Microorganisms for the production of 1,4-butanediol, 4-hydroxybutanal, 4-hydroxybutyryl-coa, putrescine and related compounds, and methods related thereto |
US20110129899A1 (en) * | 2009-10-13 | 2011-06-02 | Robert Haselbeck | Microorganisms for the production of 1,4-butanediol, 4-hydroxybutanal, 4-hydroxybutyryl-coa, putrescine and related compounds, and methods related thereto |
US8377667B2 (en) | 2009-10-13 | 2013-02-19 | Genomatica, Inc. | Microorganisms for the production of 1,4-butanediol, 4-hydroxybutanal, 4-hydroxybutyryl-CoA, putrescine and related compounds, and methods related thereto |
US9222113B2 (en) | 2009-11-25 | 2015-12-29 | Genomatica, Inc. | Microorganisms and methods for the coproduction 1,4-butanediol and gamma-butyrolactone |
US8530210B2 (en) | 2009-11-25 | 2013-09-10 | Genomatica, Inc. | Microorganisms and methods for the coproduction 1,4-butanediol and gamma-butyrolactone |
US10662451B2 (en) | 2009-11-25 | 2020-05-26 | Genomatica, Inc. | Microorganisms and methods for the coproduction 1,4-butanediol and gamma-butyrolactone |
US9988656B2 (en) | 2009-11-25 | 2018-06-05 | Genomatica, Inc. | Microorganisms and methods for the coproduction 1,4-butanediol and gamma-butyrolactone |
WO2011068952A1 (en) | 2009-12-02 | 2011-06-09 | Entrigue Surgical, Inc. | Devices for tongue stabilization |
WO2011142865A3 (en) * | 2010-02-12 | 2012-11-08 | Gevo, Inc. | Yeast microorganisms with reduced by-product accumulation for improved production of fuels, chemicals, and amino acids |
US9506074B2 (en) | 2010-02-12 | 2016-11-29 | Gevo, Inc. | Yeast microorganisms with reduced by-product accumulation for improved production of fuels, chemicals, and amino acids |
US20110201090A1 (en) * | 2010-02-12 | 2011-08-18 | Gevo, Inc. | Yeast microorganisms with reduced by-product accumulation for improved production of fuels, chemicals, and amino acids |
GB2492267B (en) * | 2010-02-12 | 2013-05-01 | Gevo Inc | Yeast microorganisms with reduced by-product accumulation for improved production of fuels, chemicals and amino acids |
GB2492267A (en) * | 2010-02-12 | 2012-12-26 | Gevo Inc | Yeast microorganisms with reduced by-product accumulation for improved production of fuels, chemicals and amino acids |
US8445244B2 (en) | 2010-02-23 | 2013-05-21 | Genomatica, Inc. | Methods for increasing product yields |
US8048661B2 (en) | 2010-02-23 | 2011-11-01 | Genomatica, Inc. | Microbial organisms comprising exogenous nucleic acids encoding reductive TCA pathway enzymes |
US8637286B2 (en) | 2010-02-23 | 2014-01-28 | Genomatica, Inc. | Methods for increasing product yields |
US10111774B2 (en) | 2011-01-27 | 2018-10-30 | Cryosa, Inc. | Apparatus and methods for treatment of obstructive sleep apnea utilizing cryolysis of adipose tissues |
US9439805B2 (en) | 2011-01-27 | 2016-09-13 | Cryosa, Llc | Apparatus and methods for treatment of obstructive sleep apnea utilizing cryolysis of adipose tissues |
US9078634B2 (en) | 2011-01-27 | 2015-07-14 | Cryosa, Llc | Apparatus and methods for treatment of obstructive sleep apnea utilizing cryolysis of adipose tissues |
US11419757B2 (en) | 2011-01-27 | 2022-08-23 | Cryosa, Inc. | Apparatus and methods for treatment of obstructive sleep apnea utilizing cryolysis of adipose tissues |
WO2012142100A1 (en) | 2011-04-13 | 2012-10-18 | Metabolix, Inc. | Biodegradable coextruded multilayer films |
WO2012149407A1 (en) | 2011-04-29 | 2012-11-01 | Metabolix, Inc. | Process for latex production by melt emulsification |
US9663791B2 (en) * | 2011-04-29 | 2017-05-30 | Cj Research Center Llc | Green process for producing polyhydroxyalkanoates and chemicals using a renewable feedstock |
US20140234944A1 (en) * | 2011-04-29 | 2014-08-21 | Metabolix, Inc. | Green Process for Producing Polyhydroxyalkanoates and Chemicals Using a Renewable Feedstock |
US9770232B2 (en) | 2011-08-12 | 2017-09-26 | W. L. Gore & Associates, Inc. | Heart occlusion devices |
US11085015B2 (en) | 2012-06-04 | 2021-08-10 | Genomatica, Inc. | Microorganisms and methods for production of 4-hydroxybutyrate, 1,4-butanediol and related compounds |
US11932845B2 (en) | 2012-06-04 | 2024-03-19 | Genomatica, Inc. | Microorganisms and methods for production of 4-hydroxybutyrate, 1,4-butanediol and related compounds |
US9677045B2 (en) | 2012-06-04 | 2017-06-13 | Genomatica, Inc. | Microorganisms and methods for production of 4-hydroxybutyrate, 1,4-butanediol and related compounds |
EP3424990A1 (en) | 2012-06-05 | 2019-01-09 | CJ CheilJedang Corporation | Biobased rubber modified biodegradable polymer blends |
WO2013184822A1 (en) | 2012-06-05 | 2013-12-12 | Metabolix, Inc. | Biobased rubber modified biodegradable polymer blends |
US10465213B2 (en) | 2012-08-10 | 2019-11-05 | Cargill, Incorporated | Microorganisms and methods for the production of fatty acids and fatty acid derived products |
WO2014028943A1 (en) | 2012-08-17 | 2014-02-20 | Metabolix, Inc. | Biobased rubber modifiers for polymer blends |
US10828019B2 (en) | 2013-01-18 | 2020-11-10 | W.L. Gore & Associates, Inc. | Sealing device and delivery system |
US11771408B2 (en) | 2013-01-18 | 2023-10-03 | W. L. Gore & Associates, Inc. | Sealing device and delivery system |
US9512057B2 (en) | 2013-03-15 | 2016-12-06 | Cargill, Incorporated | 3-hydroxypropionic acid compositions |
US10155937B2 (en) | 2013-03-15 | 2018-12-18 | Cargill, Incorporated | Acetyl-CoA carboxylases |
US10047383B2 (en) | 2013-03-15 | 2018-08-14 | Cargill, Incorporated | Bioproduction of chemicals |
US10815473B2 (en) | 2013-03-15 | 2020-10-27 | Cargill, Incorporated | Acetyl-CoA carboxylases |
WO2014194220A1 (en) | 2013-05-30 | 2014-12-04 | Metabolix, Inc. | Recyclate blends |
US11408013B2 (en) | 2013-07-19 | 2022-08-09 | Cargill, Incorporated | Microorganisms and methods for the production of fatty acids and fatty acid derived products |
US10337038B2 (en) | 2013-07-19 | 2019-07-02 | Cargill, Incorporated | Microorganisms and methods for the production of fatty acids and fatty acid derived products |
US12129506B2 (en) | 2013-07-19 | 2024-10-29 | Cargill, Incorporated | Microorganisms and methods for the production of fatty acids and fatty acid derived products |
US10368853B2 (en) | 2014-06-06 | 2019-08-06 | W. L. Gore & Associates, Inc. | Sealing device and delivery system |
US9808230B2 (en) | 2014-06-06 | 2017-11-07 | W. L. Gore & Associates, Inc. | Sealing device and delivery system |
US11298116B2 (en) | 2014-06-06 | 2022-04-12 | W. L. Gore & Associates, Inc. | Sealing device and delivery system |
US10494654B2 (en) | 2014-09-02 | 2019-12-03 | Cargill, Incorporated | Production of fatty acids esters |
US11534335B2 (en) | 2014-10-01 | 2022-12-27 | Cryosa, Inc. | Apparatus and methods for treatment of obstructive sleep apnea utilizing cryolysis of adipose tissues |
US11091632B2 (en) | 2015-11-17 | 2021-08-17 | Cj Cheiljedang Corporation | Polymer blends with controllable biodegradation rates |
WO2017087658A1 (en) | 2015-11-17 | 2017-05-26 | Cj Research Center, Llc | Polymer blends with controllable biodegradation rates |
US11345938B2 (en) | 2017-02-02 | 2022-05-31 | Cargill, Incorporated | Genetically modified cells that produce C6-C10 fatty acid derivatives |
US12123045B2 (en) | 2017-02-02 | 2024-10-22 | Cargill, Incorporated | Genetically modified cells that produce C6-C10 fatty acid derivatives |
US11535873B2 (en) | 2017-09-07 | 2022-12-27 | The Governing Council Of The University Of Toronto | Production of glycolate from ethylene glycol and related microbial engineering |
US11845973B2 (en) | 2018-03-15 | 2023-12-19 | Lg Chem, Ltd. | Poly(3-hydroxypropionate-b-lactate) block copolymer using microorganisms |
US11286510B2 (en) | 2018-03-15 | 2022-03-29 | Lg Chem, Ltd. | Poly(3-hydroxypropionate-b-lactate) block copolymer using microorganisms |
Also Published As
Publication number | Publication date |
---|---|
EP1305439A2 (en) | 2003-05-02 |
JP4860094B2 (en) | 2012-01-25 |
DE60120415T2 (en) | 2007-01-04 |
ATE329048T1 (en) | 2006-06-15 |
US8741624B2 (en) | 2014-06-03 |
WO2002008428A3 (en) | 2003-01-09 |
EP1305439B1 (en) | 2006-06-07 |
WO2002008428A2 (en) | 2002-01-31 |
KR20040014389A (en) | 2004-02-14 |
US20100021919A1 (en) | 2010-01-28 |
JP2004512825A (en) | 2004-04-30 |
DE60120415D1 (en) | 2006-07-20 |
AU2001275996B2 (en) | 2005-08-04 |
AU7599601A (en) | 2002-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8741624B2 (en) | Production of polyhydroxyalkanoates from polyols | |
AU2001275996A1 (en) | Production of polyhydroxyalkanoates from polyols | |
US5811272A (en) | Method for controlling molecular weight of polyhydroxyalkanoates | |
US6329183B1 (en) | Polyhydroxyalkanoate production from polyols | |
US6913911B2 (en) | Transgenic microbial polyhydroxyalkanoate producers | |
EP2376622B1 (en) | Green process and compositions for producing poly(5hv) and 5 carbon chemicals | |
US8093022B2 (en) | Polyhydroxyalkanoate biopolymer compositions | |
JP2008029218A (en) | Method for producing copolymerized polyester by using microorganism having lowered enzymatic activity | |
JP2008086238A (en) | Method for producing polyhydroxyalkanoate | |
EP1700909B1 (en) | Transgenic microbial polyhydroxyalkanoate producers | |
eutropha Strains | Production of Poly (3-Hydroxybutyrate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: METABOLIX, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SKRALY, FRANK A.;SHOLL, MARTHA;REEL/FRAME:012536/0545 Effective date: 20010917 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |